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Introduction  
 
 
 
 
B chronic lymphocytic leukemia 
 
B chronic lymphocytic leukemia (B-CLL) is the adult leukemia with the highest incidence in 
Western countries; more than 15.000 newly diagnosed cases and 4.500 deaths are currently 
estimated yearly. It is characterized by the clonal proliferation and accumulation of differentiated 
CD5+/CD23+ B lymphocytes in the peripheral blood and lymphoid organs [1,2]. B-CLL is an 
heterogeneous disorder in terms of progression, therapeutic response and outcome despite a 
common diagnostic immunophenotype (surface expression of CD19+, CD20+dim, CD5+, CD23+ and 
sIgMdim) [2]. The leukemic transformation is initiated by specific genomic alterations, in particular 
deletions on the long arm of chromosome 13 [del(13q14)]. Additional aberrations of the long arm of 
chromosome 11 [del(11q)], of the short arm of chromosome 17 [del(17p)] and trisomy of 
chromosome 12 seem to occur later in the course of the disease and predict a worse outcome [3-5]. 
The diagnosis of CLL is currently based on clinical analyses of lymphocyte morphology and 
the presence of >5x109/l circulating clonal B cells with the specific immunophenotype persisting for 
>3 months [1]. A recommended scoring system allocates one point each for the expression of weak 
surface membrane immunoglobulins, CD5, CD23 and absent or low expression of CD79b and 
FMC7. Using this system, 92% of B-CLL cases score 4 or 5, 6% score 3 and 2% score 1 or 2 [1]. 
Frequently at diagnosis patients present lymphadenopathy and systemic symptoms such as 
tiredness, night sweats and weight loss; signs of advanced stages of leukemia include impaired 
function of normal bone marrow elements, such as anemia and leucopenia, with higher susceptibility 
to infections [1]. 5-15% of B-CLL patients develop diffuse large B cell lymphoma (Richter syndrome) 
or, less frequently, Hodgkin lymphoma, either pre- or post-therapy. Clinical features suggestive of 
transformation include bulky (>5 cm) lymphoadenopathy, rapid nodal enlargement, extranodal 
disease, the development of B symptoms and marked elevation of lactate dehydrogenase (LDH). 
Moreover, autoimmune complications are common in B-CLL, occurring in 10-20% of patients and 
they target almost exclusively blood cells, in particular erythrocytes. The diagnosis of autoimmune 
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haemolytic anemia is based on the presence of an isolated reduction in haemoglobin with positive 
direct antiglobulin test, a rise in reticulocyte count, bilirubin and LDH and a reduction in serum 
haptoglobins [1]. Whereas the course of disease is indolent in some patients, it is steadily 
progressive in approximately half of patients, leading to substantial morbidity and mortality [2]. The 
variable clinical course of B-CLL is due, at least in part, to the disease's immunogenetic and 
molecular heterogeneity [2]. 
Numerous clinical and laboratory parameters have been developed to predict prognosis. 
Clinical staging systems of Binet and Rai still represent the most useful mean to determine prognosis 
and permit to divide patients into classes with different risk levels (Table 1) [1]. Commonly clinicians 
initiate therapeutic treatment only if patients reach advanced stages and develop a symptomatic 
disorder. However, while these staging systems are clinically useful, they can't predict long-term 
survival with high precision, especially for patients with early stage leukemia [6]. 
 
Table 1. Staging systems in CLL. 
 
BINET Stage  Features 
A  <3 Lymphoid areas* 
B  3 Lymphoid areas 
C  Haemoglobin < 100 g/l 
or platelet count < 100 9 109/l 
   
RAI Stage Risk group Features 
0 Low Lymphocytosis only 
I  Lymphadenopathy 
II Intermediate Hepatomegaly or splenomegaly 
+ lymphocytosis 
III/IV High Haemoglobin < 110 g/l or 
platelet count < 100x109/l 
*The five lymphoid areas comprise: uni or bilateral cervical, axillary and inguinal lymphoid, hepatomegaly and splenomegaly. 
 
Prognostic markers in B-CLL 
The ability to predict a more aggressive disease course has improved with the use in clinical 
practice of tests for biologic markers (degree of somatic hypermutation in the variable region of the 
immunoglobulin heavy chain [IGHV] gene and expression of ZAP-70 [Z-associated protein 70] or 
CD38) and cytogenetic abnormalities [3,7-10]. High expression of both ZAP-70 or CD38 are 
associated with higher-risk CLL. While IGHV mutated CLL patients frequently show mild clinical 
features and high overall survival and progression-free survival, IGHV un-mutated CLL patients 
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suffer an aggressive form of the disease which may be refractory to treatment [11]. Moreover, 
although the somatic mutation status is highly associated with prognosis, recent data document that 
a specific heavy chain variable region genetic signature is associated with poor prognosis, 
independently of somatic mutational status [12].  
Despite the relatively stable karyotype in CLL cells, genomic aberrations were recognized as 
important determinants of the clinical course of the disease [13]. In particular, chromosomal 
abnormalities represent strong independent predictors of prognosis in B-CLL. The most common is 
del(13q14.3), followed by del(11q22.3), trisomy 12, del(6q21-23) and del(17p13.1). As the sole 
chromosomal defect, del(13q14) is associated with a good prognosis [5,13,14]. In contrast, del(6q21-
23), del(11q22.3), del(17p13.1), del(13q14.3) with other abnormalities, and trisomy 12 are 
associated with more rapid disease progression and reduced survival [13]. Finally, the deletions in 
chromosome 17p, containing the TP53 gene, and chromosome 11q, containing the ATM gene, 
represent the most important independent cytogenetic markers of poor prognosis [5]. 
Still, even with these advances, prediction of the disease course is not highly reliable, and 
the genomic events that dictate the initiation and heterogeneous evolution of B-CLL remained 
partially unknown [15,16]. Next-generation sequencing (NGS) studies have revealed previously 
unrecognized genetic lesions, uncovering recurrent somatic gene mutations that occur in B-CLL cells 
in parallel to the above-mentioned structural genomic aberrations [3-5,16,17]. These studies 
described about 1,000 somatic variants per patient, evidencing a marked genetic heterogeneity of 
the disease, with a relatively large number of genes recurrently mutated at low frequency and only a 
few genes mutated in more than 10% of the patients [5,10,18,19].  
Among genes that are mutated at significant frequencies, TP53, ATM, MYD88 and NOTCH1 
have been described previously in chronic lymphocytic leukemia [3,5,20-24]. TP53 mutations were 
detected in 15% of patients and most of them in CLL represent missense substitutions affecting the 
structural DNA-binding domain (DBD) of p53 protein (codons 175, 179, 248, 273, and 281) that is 
critical for its tumor-suppressor activity [5,21,22,25], with one mutation out of 105 cases in Quesada 
et al. [4] and 15 mutations out of 91 cases in Wang et al. [5]. The proportion of patients with a sole 
TP53 mutation [without del(17p)] vary from 3% to 4% among cohorts at diagnosis or before first 
therapy [21] to 12% in fludarabine-refractory CLL [26]. A prognostic impact of TP53 mutations in B-
CLL has been suggested in a number of reports [21]. Patients with defective p53 have a significantly 
lower response rate to therapy and a short-progression-free survival [22]. Indeed, TP53 mutation and 
related alterations have been associated with disease progression and chemorefractoriness in B-
CLL [27,28]. Additionally, although TP53 mutations in naïve B-CLL were usually considered a rare 
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(<5%) event [29,30], a recent study performed using the ultra-deep next generation sequencing 
technology demonstrated that very small TP53 mutated subclones (minor than 20%) are present in 
9% of newly diagnosed B-CLL patients [31]. Of note, patients harboring small TP53 mutated 
subclones showed the same clinical phenotype and poor overall survival as patients carrying clonal 
TP53 lesions [31]. In addition, the percentage of TP53 mutations dramatically increases up to >30% 
after relapsed chemotherapy [32]. According to the revised National Cancer Institute (NCI) Working 
Group/International Workshop on Chronic Lymphocytic Leukemia guidelines for B-CLL, patients with 
del(17p) should be offered investigative clinical protocols or should be listed for allogeneic stem-cell 
transplantation [22]. 
9% of patients with B-CLL present mutations in ATM [5,20]. The ataxia telangiectasia 
mutated (ATM) protein kinase acts upstream of the p53 oncoprotein and coordinates an integrated 
cellular response to DNA double-strand breaks through phosphorylation of multiple target proteins. 
This results in the interruption of the cell cycle and either DNA repair or activation of apoptosis 
[20,33]. The ATM tumor suppressor gene is located within the minimally deleted region on 
chromosome 11q. Deletions of chromosome 11q were associated with a severe clinical phenotype 
and reduced overall survival in B-CLL. ATM mutations were associated with un-mutated IGVH genes 
and they provided independent prognostic information on multivariate analysis [20]. 
In addition, recurrent mutations in the myeloid differentiation primary response gene 88 
(MYD88) were also identified in 10% of CLL patients [5]. This protein participates in the signalling 
pathways of interleukin-1 and Toll-like receptors during the immune response [34]. The missense 
mutations are localized within the interleukin-1 receptor–TLR domain [4,24], and they were 
documented to activate this proto-oncogene, promoting the duplication of tumour cells and protecting 
from apoptosis [24,35,36]. Patients with MYD88-mutated CLL were diagnosed at a younger age and 
with a more advanced clinical stage [3]. 
Finally, NOTCH1 mutations affect 5–10% of newly diagnosed B-CLL cases, with their 
prevalence increasing to 15–20% in progressive or relapsed patients [23]. NOTCH1 is constitutively 
expressed by B-CLL cells, where it increases cell survival and induces apoptosis resistance [37-39]. 
A recurrent mutation is due to the deletion of a CT dinucleotide (p.P2515Rfs*4), generating a 
truncated protein which is predicted to result in NOTCH1-impaired degradation and stabilizing effect 
on the NOTCH1 signaling pathway [3,16]. Indeed both the canonical and non-canonical NOTCH1 
pathways are constitutively upregulated in NOTCH1-mutated patients [16]. NOTCH1-mutated 
patients had a more advanced clinical stage at diagnosis, more adverse biological features and an 
overall survival that was significantly shorter than those with wild-type NOTCH1 [3,10,23,38]. 
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Interestingly, on a clinical perspective, among the novel genes that are recurrently mutated 
in CLL, some are preferentially altered in fludarabine refractoriness (FR) patients, namely TP53, 
NOTCH1, SF3B1 and BIRC3 [23,25,40,42]. FR remains an unsolved clinical problem associated 
with poor survival, involving 10% of patients after first-line treatment and virtually all patients after 
multiple lines of therapy [43,44]. Until recently, the molecular basis of CLL chemorefractoriness was 
incompletely characterized, and the only known genetic lesion with an established pathogenic role 
was inactivation of the TP53 gene occurring in 30% to 40% of refractory patients [26]. Interestingly, 
mutations of the splicing factor 3b, subunit 1 (SF3B1) gene have been identified in 15% of B-CLL 
patients [5] and they are recurrently associated with fludarabine-refractory CLL and poor clinical 
prognosis, with a frequency significantly greater than that observed in a consecutive CLL cohort 
sampled at diagnosis [40]. Therefore, SF3B1 mutated B-CLL require prompt treatment, 
independently of other established predictive markers [4,45].  
In conclusion, somatic mutations affecting NOTCH1, SF3B1 and TP53 are improving our 
ability to predict the outcome of the disease from early stages [41,46], and several studies have been 
performed to clinically characterize the consequences of mutations affecting these genes on the 
prognosis of CLL. In a recent manuscript Landau et al. have shown that the presence of certain 
somatic mutations even in a small population of the tumor cells accurately predicts a high probability 
of relapse after treatment [17]. If this information is known at diagnosis, clinicians may choose to 
target those drivers early to prevent relapse [47]. 
 
 
Current management of chronic lymphocytic leukemia 
 
The clinical course of patients with B chronic lymphocytic leukemia spans from an 
asymptomatic disease never requiring therapy to a rapidly progressive disorder requiring intensive 
treatment [2] The clinical heterogeneity of B-CLL and advanced age of a great number of subjects 
dictate that a diversified therapeutic approach, since no single treatment is applicable to all patients 
[1]. For more than 40 years, B-CLL has been treated with diverse chemotherapies [43]. Monotherapy 
with cytostatic alkylating agents, usually chlorambucil (CLB), has been used for several decades as 
initial, front-line therapy [48]; the principal limits of CLB are due to low or nonexistent complete 
remission (CR) rate and serious side effects after extended use, i.e. prolonged cytopenia, 
myelodysplasia and secondary acute leukemia [43,48,49]. Combinations of alkylating drugs with 
vinca alkaloids or anthracycline drugs did not improve outcomes [48]. Three purine analogs are 
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currently used in B-CLL, fludarabine, pentostatin, and cladribine (2-CdA). Fludarabine induced more 
partial remissions (PR) and more complete remissions (CR) (7%-40%) than other conventional 
chemotherapies, but did not improve overall survival (OS) when used as single agent [1,50]. 
A great collection of clinical data confirms that a combination of chemotherapies has proven 
more effective compared to monotherapy [49]. Since purine analogs and alkylating agents have 
different mechanisms of action and partially non-overlapping toxicity profiles, they were combined 
both in preclinical and clinical studies. The most thoroughly studied combination chemotherapy for B-
CLL is fludarabine plus cyclophosphamide (FC) given as oral drugs or intravenous infusions [51]. 
Three randomized trials have demonstrated that FC chemotherapy improves clinical response, 
progression-free survival (PFS) and complete remission compared with fludarabine monotherapy 
[52-54]. An updated analysis of the CLL4 trial of the German CLL Study Group (GCLLSG) suggested 
that the front-line treatment of B-CLL patients with FC combination might improve the OS of the non-
high-risk B-CLL patients [all patients without del(17p) or TP53 mutation] [49]. 
Chemo-immunotherapy was developed for the treatment of indolent and aggressive 
lymphoma. Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen expressed 
on B-cells, became the standard drug for different B-cell lymphomas [42,55]. In B-CLL the 
expression of the CD20 antigen on leukemic cells is relatively low and standard-dose rituximab 
generates only poor response rates [43,56]. The results of phase 2 trials suggested that rituximab in 
combination with chemotherapy might have additive or synergistic effects in pretreated and 
treatment-naive patients [57,58]. In a study of 300 treatment-naïve patients, the combination of FC 
with rituximab resulted in an overall response rate of 95%, with 72% of patients achieving a complete 
response [43,57,58]. These response rates were among the highest reported so far for first-line 
treatments in patients with B-CLL [43]. Furthermore, this clinical study documented that patients with 
del(11q) presented complete remission after chemo-immunotherapy and patients with trisomy 12 
and del(13q) greatly benefited from treatment. On the contrary, patients with del(17p), associated 
with a dysfunction of the p53 tumour suppressor and a very poor outcome, might not benefit 
substantially [43]. 
Immunotherapies for B-CLL treatment include other two drugs, which demonstrate 
therapeutic efficacy. Ofatumumab is a fully humanized antibody targeting the CD20 antigen, that 
induces an increased cell death due to greater complement-dependent cytotoxicity and similar 
antibody-dependent cellular-cytotoxicity activity compared with rituximab. Ofatumumab has shown 
some efficacy in patients with fludarabine and alemtuzumab refractory or bulky disease [59]. 
Alemtuzumab is a recombinant, fully humanized monoclonal antibody against the CD52 antigen. 
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Monotherapy with alemtuzumab had high response rates in patients with advanced B-CLL previously 
treated with alkylating agents and in patients nonresponsive or relapsed after second-line fludarabine 
therapy [49]. In addition, alemtuzumab has proven effective in patients with high-risk genetic markers 
such as deletions of chromosome 11 or 17 and TP53 mutations [60]. 
Currently numerous new compounds that target a relatively specific signaling defect or 
redirect the immune system against B-CLL cells are in clinical development [61,62]. These agents 
show clinical efficacy and may yield response rates above 50% even in relapsed and refractory CLL 
patients [43]. In particular, agents targeting B cell receptor (BCR) signaling have entered in phase 3 
trials for B-CLL patients. Stimulation of BCR induces the activation of different tyrosine kinases, such 
as Bruton tyrosine kinase (BTK), spleen tyrosine kinase (Syk), ZAP-70, Src family kinases, and 
phosphatidyl inositol 3-kinase (PI3K), which stimulate malignant B-cell survival via activation of 
transcription factors such as NF-kB [61,63]. Idelalisib (CAL-101), an oral PI3Kp100  isoform–
selective inhibitor, promotes apoptosis selectively in primary B-CLL cells, without reducing antibody-
dependent cellular cytotoxicity [64]. In a phase 1 clinical trial in 54 heavily pretreated and high-risk B-
CLL patients, idelalisib showed acceptable toxicity, positive pharmacodynamics effects, and 
favorable clinical activity. An overall response rate (ORR) of 56% was achieved, with 2 CRs and 28 
PRs [65]. 
Ibrutinib (PCI-32765) is an orally active small molecule inhibiting BTK, which activates cell 
survival pathways such as NF-kB and MAPKs via Src family kinases. Inhibition of BTK might induce 
apoptosis in B-cell lymphomas and B-CLL cells [66]. Ibrutinib showed significant activity in patients 
with relapsed or refractory B-CLL [67]. Data from a phase 1b-2 multicenter study with single-agent 
ibrutinib on 85 patients with relapsed or refractory B-CLL or small lymphocytic lymphoma, the 
majority with high-risk disorder, were published recently [68]. The ORR was 71%, the majority being 
PRs (68%). Interestingly, the response was independent of clinical and genomic risk factors, 
including advanced stage disease, the number of previous therapies and del(17p). This study 
illustrates that ibrutinib may soon become an additional treatment option for B-CLL patients with 
high-risk genetic lesions [68]. The above described novel therapies, targeting specific signaling 
proteins of B-CLL cells, present a moderate overall toxicity, without myelosuppression. However, 
CRs have not occurred frequently so far with any of these newer agents [43]. 
Patients who relapse and have not acquired a TP53 abnormality can be expected to respond 
to a further course of their initial therapy, although the PFS is usually shorter than after initial therapy 
and repeated courses often lead to drug resistance. However, re-treatment with the previous therapy 
is not recommended in patients whose initial treatment was sub-optimal or if a new treatment, shown 
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to be superior to the initial therapy, becomes available [1]. For patients with high risk B-CLL (TP53 
defect and/or failing fludarabine combination therapy within 2 years), results of phase II and III 
studies using either FC, FCR or alemtuzumab, with or without high dose steroids, indicate that 
alemtuzumab plus pulsed methylprednisolone or dexamethasone should be regarded as the 
induction regimen of choice. However, this regimen is associated with a significant risk of infection 
and the duration of remission is relatively short. Allogeneic stem-cell transplantation provides the last 
opportunity of achieving long-term disease-free survival for patients with high-risk B-CLL, particularly 
those with TP53 defects [1,43].  
 
 
Metabolic transformation in cancer 
 
Over the past 25 years, the oncogene revolution has stimulated the research in cancer 
biology, revealing that the crucial phenotypes of tumour cells result from a host of mutational events 
that combine to alter multiple core signaling pathways [69,70]. High-throughput sequencing data 
suggest that the mutations leading to tumorigenesis are even more numerous and heterogeneous 
than previously thought [71]. Indeed, gene set enrichment analysis showed significant up-regulation 
of several core processes, known to participate also in cancer metabolic reprogramming, such as 
glycolysis/gluconeogenesis, the pentose phosphate pathway or oxidative phosphorylation [72,73]. 
Multiple key oncogenic signalling pathways converge to adapt tumour cell metabolism in order to 
support their growth and survival. Some of these metabolic alterations, that is rapid ATP generation, 
increased biosynthesis of macromolecules and tightened maintenance of cellular redox status, seem 
to be absolutely required for malignant transformation. Therefore, altered cellular metabolism 
represents one of the emerging hallmark of cancer [69,73,74]. 
The most evident and most studied metabolic phenotype observed in tumour cells is the 
Warburg effect, also termed aerobic glycolysis, which describes the shift from ATP generation 
through oxidative phosphorylation to ATP generation through glycolysis [75]. Indeed while normal 
tissues used mitochondrial oxidation to account for 90% of ATP production with glycolysis 
accounting for 10%, tumor cells used less of the highly efficient oxidative phosphorylation, producing 
50% of the ATP from oxidation and 50% from glycolysis. This shift was thought to occur even though 
there is sufficient oxygen to support mitochondrial function [76,77]. The increase in glycolysis at the 
expense of mitochondrial energy production helps to support unbridled growth, provide precursors 
for the biosynthesis of macromolecules and protect cells from excessive and toxic levels of reactive 
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oxygen species (ROS) and oxidative stress [69]. This hypothesis greatly influenced the present 
perception of cancer metabolism, moving aerobic glycolysis into the mainstream of clinical oncology. 
 
 
 
Figure 1. Molecular mechanisms driving the Warburg effect. Relative to normal cells (part a) the shift to 
aerobic glycolysis in tumour cells (part b) is driven by multiple oncogenic signalling pathways. PI3K activates AKT, 
which stimulates glycolysis by directly regulating glycolytic enzymes and by activating mTOR. The liver kinase B1 
(LKB1) tumour suppressor, through AMP-activated protein kinase (AMPK) activation, opposes the glycolytic 
phenotype by inhibiting mTOR. mTOR induces the glycolytic phenotype by enhancing hypoxia-inducible factor 1 
(HIF1) activity, which engages a hypoxia-adaptive transcriptional programme. HIF1 increases the expression of 
glucose transporters (GLUT), glycolytic enzymes and pyruvate dehydrogenase kinase, isozyme 1 (PDK1), which 
blocks the entry of pyruvate into the tricarboxylic acid (TCA) cycle. MYC cooperates with HIF in activating several 
genes that encode glycolytic proteins, but also increases mitochondrial metabolism. The tumour suppressor p53 
opposes the glycolytic phenotype by suppressing glycolysis through TP53-induced glycolysis and apoptosis 
regulator (TIGAR), increasing mitochondrial metabolism via SCO2 and supporting expression of PTEN. OCT1 acts 
in an opposing manner to activate the transcription of genes that drive glycolysis and suppress oxidative 
phosphorylation. The switch to the pyruvate kinase M2 (PKM2) isoform affects glycolysis by slowing the pyruvate 
kinase reaction and diverting substrates into alternative biosynthetic and reduced nicotinamide adenine 
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dinucleotide phosphate. (NADPH)-generating pathways. MCT, monocarboxylate transporter; PDH, pyruvate 
dehydrogenase. The dashed lines indicate loss of p53 function. Image from Cairns et al,2011. 
 
Recent advances in genomics and proteomics have provided insights into molecular 
mechanisms which underline the metabolic remodelling occurring in cancer cells [73,75]. Metabolic 
pathways in normal cells are tightly regulated and all parts of these networks can be highly perturbed 
in cancer cells [78]. Mutations in oncogenes and tumour suppressor genes cause alterations to 
multiple intracellular signaling pathways that affect tumour cell metabolism and reengineer it to allow 
enhanced survival and growth [69,71]. Consistently genetic analysis of tumors has since identified 
numerous oncogenes that, once activated, increase glycolysis and glutaminolysis, and, analogously, 
different tumor suppressor that, once lost, can shift energy production away from the mitochondria to 
a more glycolytic equilibrium [75,79]. Irrespective of the mechanisms involved, if certain tumors are 
reliant on glycolysis for bioenergetics, biosynthesis and invasive potential, therapeutic targeting of 
the underlying pathways may result in an anti-tumor activity (Figure 1) [79,80]. Indeed drugs that can 
selectively target the metabolic phenotype of the tumour are likely to at least delay tumour 
progression [74]. The resistance of tumours to both radiotherapy and chemotherapy can often be 
attributed to its aberrant metabolism. Therefore the reactivation of a more ‘normal’ metabolism could 
re-sensitize tumours to these agents. From a therapeutic perspective, knowledge of cancer cell 
metabolism will enable the identification of new drug targets and will facilitate the design of a new 
class of cancer therapeutics and diagnostic tools especially exciting [69]. The ultimate aim is to 
develop treatment strategies that slow tumour progression, improve the response to therapy and 
result in a positive clinical outcome [81]. Therapies that target tumour metabolism are currently being 
tested in pre-clinical and clinical studies [74]. 
 
Metabolism in chronic lymphocytic leukemia 
Despite the high incidence of B chronic lymphocytic leukemia, metabolism of B-CLL cells 
remains a relatively unexplored field [82]. Although initially demonstrated in solid tumors, a recent 
study identified dysregulated glucose metabolism as a novel therapeutic target also in B-CLL [83]. In 
particular glycolytic enzymes appeared to be upregulated in a subset of CLL patients with either 
higher white blood cell counts and/or more aggressive clinical course. Additionally recent evidences 
documented that in leukemic cells mitochondrial uncoupling, i.e. the reduction in ATP synthesis in 
response to mitochondrial membrane potential, due to the overexpression of uncoupling protein 
UCP2, promotes glycolysis, increases the apoptotic threshold and induces chemo-resistance [84].  
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Results from few studies indicate that B-CLL cells might contribute to the so-called cancer-
associated oxidative stress [85]. This metabolic condition results from accumulating reactive oxygen 
species (ROS) [86], compared with normal B-cell, due to cancer-related mitochondrial alterations, 
such as defective oxidative phosphorylation or an enhanced mitochondrial biogenesis [87]. 
Moreover, high levels of ROS correlated with the number of circulating CLL cells and have been 
detected in more aggressive B-CLL cells [88]. Mitochondria were identified as the key source for 
abundant ROS in B-CLL [76,82]. Escalated ROS levels promote genetic instability and development 
of drug resistance, determine alterations in cell-signaling [86] and altogether account for cancer cells’ 
aggressive behavior [82]. This is in line with studies demonstrating that B-cell stimulation promotes 
ROS production [89] and B-CLL cells partially resemble chronically activated B-cells [90]. Oxidative 
stress additionally attenuates immune responses by leading to dysfunctions and even apoptosis of 
NK- and T-cells, suggesting a role in tumor immune-escape [82]. Since cancer cells are continuously 
exposed to high levels of endogenous ROS, cells which adapt to high stress condition are 
preferentially selected. Consequently, an enhanced protective antioxidant capacity is reported in 
tumors, which in addition induce the development of drug resistance [91]. As a protective measure, 
the activation of the redox adaptive cascade (through increased expression of intracellular 
antioxidant catalase and the stress-responsive heme oxygenase-1, and reduced expression of 
mitochondrial manganese superoxide dismutase) would then additionally promote biogenesis of 
novel and functional mitochondria [82]. Thus increased mitochondrial ROS, adaptation to intrinsic 
oxidative stress and mitochondrial biogenesis are interconnected in B-CLL. 
Interestingly, using agents that further aggravate mitochondrial ROS production and thereby 
overwhelm the cancer cells’ protective systems could selectively induce apoptosis in B-CLL cells 
[82]. Metabolic alterations can render malignant cells more susceptible to perturbations and therefore 
agents directed against the unique metabolic features of B-CLL cells might represent an opportunity 
to improve current therapeutic treatments and even to overcome drug resistance within B-CLL cells. 
 
Targeting aerobic glycolysis in chronic lymphocytic leukemia 
Several recent studies have confirmed that restricting glycolysis or diverting pyruvate into the 
mitochondria can significantly induce respiration in cancer cells [92]. The fate of pyruvate [either 
reduction in the cytosol by lactate dehydrogenase (LDH) or oxidation in the mitochondria by pyruvate 
dehydrogenase (PDH)] determines the direction of tumour metabolism. The inhibition of lactate 
dehydrogenase or the activation of pyruvate dehydrogenase can induce tumour cells to oxidize 
pyruvate in the TCA cycle and stimulate mitochondrial respiration [93-95]. Pyruvate dehydrogenase 
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represents the enzymatic step linking glycolysis to oxidative phosphorylation. One of four pyruvate 
dehydrogenase kinase (PDKs) and one of two pyruvate dehydrogenase phosphatases are 
associated with PDH and regulate the phosphorylation of the E1a subunit, dictating PDH activity. 
When phosphorylated, PDH is inactivated, resulting in channelling of pyruvate to lactate, whereas 
the non-phosphorylated form is active and converts pyruvate into mitochondrial acetyl-CoA [5]. 
Recent studies provided evidence that PDK1 expression is elevated in cancers, thereby attenuating 
mitochondrial function and respiration, and its activation may be a key regulatory switch contributing 
to the Warburg effect [5,69,70,77]. The inhibition of PDK is increasingly becoming seen as a valid 
target for cancer therapy [14,81]. Indeed ihibitors of PDK could potentially reverse some of the 
metabolic effects of tumorigenic signalling and several such candidates, including the mitochondria-
targeting dichloroacetate molecule (DCA), are currently under evaluation for their therapeutic utility 
[71,74,75]. Indeed, preclinical studies confirm the relatively low toxicity of DCA and document its 
efficacy against numerous epithelial cancers (such as non-small cell lung, endometrial, prostate, 
breast and colorectal cancer), glioblastoma, as well as multiple myeloma [96-105]. DCA inhibits 
mitochondrial pyruvate dehydrogenase kinase (PDK) reverting the metabolic-electrical remodelling 
occurring in cancer cells; indeed it shifts the metabolism from glycolysis to glucose oxidation. In 
addition, DCA decreases the mitochondrial membrane potential, increases the reactive oxygen 
species (ROS) production and ultimately induces apoptosis and tumor growth arrest in mice models, 
without apparent toxicity [95]. DCA is an orally bioavailable, small molecule and currently being 
evaluated in phase I/II clinical trials for glioblastoma, gliomas and other solid tumors [106]. 
Interestingly, in solid tumor models it has also been reported that DCA may activate p53 [107]. In 
addition, a couple of recent studies proposed DCA alone or in association with bortezomib for the 
treatment of multiple myelomas [105,108], suggesting anti-cancer activity of DCA also in 
hematological disorders. 
 
 
The oncosuppressor TP53: role in metabolic transformation 
 
Although the tumour suppressor p53 is best known for its functions in mediating the cytotoxic 
response of most therapeutic molecules currently used in cancer therapy, p53 is also an important 
regulator of metabolism [69]. The role of p53 as a central component of the stress response 
machinery is well established, and numerous forms of stress - many of which are encountered during 
tumoral transformation - lead to the activation of p53 [109]. Virtually any stress signal can induce 
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p53, including hypoxia or the lack of nutrients and deregulated signalling through the nutrient-
sensing pathways, namely the AKT–mTOR pathway [110]. Oxidative stress regulates p53 function 
by directly affecting its redox state and oxidation [111] and mitochondrial ROS represent an 
important component of the stress-induced activation of p53 [112]. Also, p53 is efficiently activated 
by ribosomal stress through the ability of several ribosomal proteins to bind and inactivate MDM2 
[113]. Combinations of these abnormalities during tumour progression amplify the protective p53 
response. However, increased glucose metabolism stimulated by the expression of the glucose 
transporter GLUT1 or hexokinase has been reported to suppress p53 activity [114], suggesting that 
high levels of glycolysis in cancer may help evade the tumour-suppressive effects of p53. The most 
obvious advantage of p53 activation under conditions of metabolic stress is a coordinated inhibition 
of cell proliferation and growth. However additional consequences of p53 activation are being 
uncovered, including an ability of p53 to promote the use of certain metabolic pathways and to 
increase cell survival.  
 
 
 
Figure 2. Regulation of energy production by p53. Several functions of p53 reduce the flux through the 
glycolytic pathway and increase oxidative phosphorylation, thereby opposing the Warburg effect, in which cancer 
cells predominantly use glycolysis for energy production. However, there are also activities of p53, such as the 
activation of hexokinase and phosphoglycerate mutase (PGM), which could increase glycolysis under some 
circumstances. GLUT, glucose transporter; IKK, IκB kinase; NF-κB, nuclear factor-κB; SCO2, synthesis of 
cytochrome c oxidase 2; TCA, tricarboxylic acid. Image from Vousden and Ryan,2009. 
 
Several studies documented that p53 exerts a role in the regulation of both glycolysis and 
oxidative phosphorylation (Figure 2) [78]. Different mechanisms have been described through which 
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p53 can slow glycolysis and therefore counteract its increase in cancer. p53 can inhibit the 
expression of the glucose transporters GLUT1 and GLUT4 and can decrease the levels of 
phosphoglycerate mutase (PGM), while increasing the expression of TP53-induced glycolysis and 
apoptosis regulator (TIGAR), which reduces the levels of the glycolytic activator fructose-2,6- 
bisphosphate [78,115]. Wild-type p53 also supports the expression of PTEN, which inhibits the PI3K 
pathway, thereby suppressing glycolysis [116] and hexokinase 2 (HK2), which converts glucose to 
glucose-6-phosphate (G6P) [117]. G6P then either enters glycolysis to produce ATP, or enters the 
pentose phosphate pathway. The effect of each of these actions is to impede flux through different 
steps of the glycolytic pathway. The restraint on glycolytic rate imposed by p53 is in accordance with 
its ability to help maintain mitochondria and drive oxidative phosphorylation [118]. These effects are 
the consequence of several p53-dependent functions, including the transcriptional activation of 
subunit I of cytochrome c oxidase [119]; the activation of expression of synthesis of cytochrome c 
oxidase 2 (SCO2), a key regulator which is required for the assembly of the cytochrome c oxidase 
complex of the electron transport chain [120]; and the induction of expression of the ribonucleotide 
reductase subunit p53R2 protein, that contributes to the maintenance of mitochondrial DNA [121]. 
Loss of either p53 or SCO2 expression results in a switch from cellular respiration to aerobic 
glycolysis, suggesting that inactivation of p53 in human cancers may directly contribute to the 
Warburg effect [75,122]. Indeed in tumors with non-functional p53 (majority of tumors), the 
mitochondrial electron-transport chain is compromised, and glycolysis is the more efficient 
mechanism for generation of ATP [80]. Interestingly, several of these p53 activities, such as the 
regulation of SCO2, seem to function under normal growth conditions in the absence of an acute 
stress signal, suggesting that p53 can help to maintain the aerobic respiration of most normal cells. 
However, the presence of p53-responsive elements in the promoters of phosphoglycerate mutase 
and hexokinase II suggests that p53 can promote at least some steps in glycolysis, resulting in 
increased survival signalling by helping to limit ROS production [78]. These different activities reflect 
context- or tissue-dependent differences in the metabolic functions of p53. Notwithstanding the role 
of p53 in enhancing oxidative phosphorylation, increased glycolysis in response to pharmacological 
inhibition of oxidative phosphorylation is reported to be dependent on p53 [123]. 
Our recent appreciation of the importance of basal levels of p53 in regulating metabolic 
pathways is mirrored by the importance of the antioxidant functions of low or uninduced levels of p53 
[124]. ROS are heterogeneous in their properties and exert a plethora of downstream effects, 
depending on the concentrations at which they are present. Low levels of ROS are required for 
homeostatic signaling events, increasing cell proliferation and survival through the post-translational 
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modification of kinases and phosphatases [125]. At moderate levels, ROS induce the expression of 
stress-responsive genes such as hypoxia-inducible factor HIF-1Α, which in turn determine the 
expression of proteins providing pro-survival signals [69]. However, once levels of ROS become 
excessively high, they cause damage to macromolecules, induce the activation of protein kinase Cδ 
(PKCδ) and senescence [126], and/or cause permeabilization of the mitochondria, with the release 
of cytochrome c and apoptosis [127]. Cells counteract these effects of ROS by producing antioxidant 
molecules, such as reduced glutathione and thioredoxin [69]. There is currently a scientific 
consensus that cancer cells alter their metabolic pathways and regulatory mechanisms so that ROS 
and antioxidants are tightly controlled and maintained at higher levels than in normal cells, in such a 
way that the cell survives and the levels of ROS are reduced to moderate levels [128,129]. The 
mechanisms designed to counter the control of ROS abundance allow the cancer cell to avoid the 
detrimental effects of high levels of ROS, but also increase the chance that cell will experience 
additional ROS-mediated mutagenic events and stress responses that promote tumorigenesis.  
p53 may promote oxidative stress while inducing apoptosis, but it also exerts an important 
role in reducing oxidative stress as a defense mechanism. Interestingly, through the p53 target gene 
cyclin-dependent kinase inhibitor 1A (CDKN1A, which encodes p21), p53 promotes the stabilization 
of the transcription factor NRF2 [130]. NRF2 is the master antioxidant transcription factor and 
upregulates the expression of several antioxidant and detoxifying molecules [130]. Loss of p53 in a 
cancer cell inactivates this redox maintenance mechanism: because p21 is not activated, NRF2 
continues to be degraded, antioxidant proteins are not expressed and the redox balance is lost [130]. 
Regulation of the glycolytic pathway by p53 can also help to modulate oxidative stress by increasing 
flux through the pentose phosphate pathway. The activation of both TIGAR and hexose-6-phosphate 
dehydrogenase would promote the pentose phosphate pathway, with the generation of NADPH that 
enters in both anabolic and antioxidant pathways [78].  
p53 can also exerts strong pro-oxidative effects. The ability of p53 to induce senescence and 
apoptosis is clearly related to the induction of oxidative stress, and even necrotic cell death is 
activated by the cooperation between ROS and p53-induced cathepsin Q expression [78]. Several 
p53-inducible proteins activated during the apoptotic response promote ROS production, including 
p53-induced gene 3 (PIG3), proline oxidase, Bax, PUMA and p66Shc [78]. To further increase this 
effect, p53 can also inhibit or modulate the expression of antioxidant genes such as superoxide 
dismutase 2 (SOD2), aldehyde dehydrogenase 4 (ALDH4) and glutathione peroxidase 1 (GPx1), 
which increases oxidative stress [78]. Less directly, the ability of p53 to drive oxidative 
phosphorylation through the activation of SCO2 will also promote the generation of ROS from the 
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mitochondria [120-122]. Depending on the cell type and the levels of ROS, the consequences of 
ROS regulation by p53 can include proliferation, migration, genotoxic damage, senescence and cell 
death. In cells in which both pro-oxidant and antioxidant responses are possible the difference lies in 
the extent and persistence of the damage-inducing stress. The regulation of ROS by p53 might be 
different under basal or low-stress conditions (in which p53 functions as an antioxidant) compared 
with high-damage and high-stress conditions (in which p53 contributes to cell death by increasing 
ROS levels) [131]. From a clinical point of view, it may be possible to exploit loss-of-function p53 
mutations or other tumour suppressor genes by applying additional oxidative stress. In the absence 
of the redox maintenance pathway that is supported by these tumour suppressors, malignant cells 
might be selectively killed [86]. 
Numerous data indicate a role of wild-type p53 in averting metabolic transformation, 
although the possible role of mutant p53 is as yet largely unexplored. TP53 incurs point mutations in 
numerous cancers, with expression of mutant p53 proteins that have acquired activities which 
contribute to malignant progression independently of the loss of wild-type p53 function. A role for 
these mutant p53 proteins in promoting the metabolic transformation would be extremely interesting. 
 
Targeting p53 with Nutlin-3 as potential therapeutic option for B-CLL 
The cellular level of the protein p53 is regulated primarily by degradation via the ubiquitin-
proteasome pathway, and the murine double minute 2 gene (MDM2) functions as a master regulator 
of p53 [132]. Vassilev et al. [133] reported the first potent and selective small molecule antagonist of 
MDM2, termed Nutlin-3. This is a cis-imidazoline analogue that binds to the p53 pocket on the 
surface of MDM2, activating the p53-pathway in vitro and in vivo. Notably, this interaction, while 
blocking MDM2-mediated inhibition of p53, does not interfere with p53 function and has little toxicity 
in animal models. In this context, Secchiero et al. demonstrated that Nutlin-3 is effective in inducing 
apoptosis in vitro in p53wild-type B-CLL samples independently of the negative prognostic markers 
[134-136], as confirmed by other authors. These studies strengthened the concept that selective, 
non-genotoxic activation of p53 might represent an alternative to the current cytotoxic chemotherapy. 
Interestingly, Nutlins not only induced apoptotic death in leukemic cells, but also showed a 
synergistic effect when used in combination with the chemotherapeutic drugs commonly used for the 
treatment of hematological disorders. Furthermore Nutlins also exert non cell-autonomous biological 
activities, such as inhibition of vascular endothelial growth factor, stromal derived factor 1/CXCL12 
and osteoprotegerin expression and/or release by primary fibroblast and endothelial cells. Moreover, 
Nutlins have a direct anti-angiogenetic and anti-osteoclastic activities. Thus Nutlins might have 
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therapeutic effects by two distinct mechanisms: a direct cytotoxic effect on leukemic cells and an 
indirect non-cell autonomous effect on tumor stromal and vascular cells, and this latter effect might 
be therapeutically relevant also for treatment of leukemia with 53 mutations [129]. Furthermore, it is 
noteworthy that, when used in association with other therapeutic compounds, Nutlin-3 showed 
synergistic cytotoxic activity also on p53mutated B-CLL cells [136,137]. 
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Objectives 
 
 
 
 
In spite of the recent therapeutic advances in the treatment of B-CLL patients, a major 
unsolved clinical problem is represented by the lack of effective treatments for B-CLL patients with 
more aggressive disease, carrying cytogenetic abnormalities affecting the p53-pathway activation 
(17p13.1 or 11q22.3 deletions), or characterized by recently identified somatic mutations in TP53, 
NOTCH1, SF3B1 and BIRC3 genes, who are less likely to respond to conventional treatments. 
Additionally, recurrent and/or relapsing disease remains a major concern. Taken together, these data 
underline the need to investigate new compounds for innovative anti-leukemic targeted therapies 
with less toxicity and increased efficacy, to be used alone or in combination with other therapeutics. 
On these bases, the broad objective of my project was to preclinically assess the effects of 
the glycolytic inhibitor DCA in B-CLL in vitro. Particular attention has been directed to assess the 
potential therapeutic efficacy towards the B-CLL subtypes characterized by poor prognosis (i.e. p53 
mutations). In order to achieve this aim, the experimental plan was structured in two phases:  
i) we assessed the cytotoxic/cytostatic effects of DCA in a collection of primary p53wild-type B-
CLL samples obtained from patients and in normal peripheral blood mononuclear cells (PBMC), as 
well as a panel of human p53wild-type B leukemic cell lines (EHEB, JVM-2, JVM-3). DCA was used 
either alone and in association with Nutlin-3. In addition, we have investigated the key intracellular 
molecular determinants mediating the activity of DCA, Nutlin-3 and Nutlin-3+DCA; 
ii) we evaluated the cytotoxic/cytostatic effect of DCA in primary p53mutated B-CLL cells and in 
human p53mutated/null leukemic cell lines (MAVER, MEC-1, MEC-2, HL-60). In order to dissect the p53-
independent molecular mechanisms of DCA cytotoxicity, a set of experiments based on proteomic 
and genomic approaches was performed using the p53null HL-60 leukemic cell line. 
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Methods 
 
 
 
 
Primary B-CLL patient samples and B leukemic cell lines  
For experiments with primary cells, peripheral blood samples were collected in heparin-
coated tubes from B-CLL patients and healthy blood donors following informed consent, in 
accordance with the Declaration of Helsinki and in agreement with institutional guidelines (University-
Hospital of Ferrara). The main clinical parameters of the B-CLL patients were abstracted from clinical 
records (Table 2). All patients had been without prior therapy at least for three weeks before blood 
collection. Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation with 
lymphocyte cell separation medium (Cedarlane Laboratories, Hornby, ON, CAN). T lymphocytes, NK 
lymphocytes, granulocytes and monocytes were negatively depleted from peripheral blood B-CLL 
with immunomagnetic microbeads (MACS microbeads, Miltenyi Biotech, Auburn, CA), with a purity 
>95% of resulting CD19+ population, as assessed by flow cytometry analysis. 
To analyze the TP53 status, selected B-CLL patients’ DNA samples obtained from 
circulating CD19+ cells were sequenced on Ion Torrent Personal Genome Machine system using a 
custom Ion AmpliSeq panel (Life Technologies, Carlsbad, CA) targeting the exonic regions and the 
exon-intron boundaries of TP53. Next generation sequencing data was annotated by a standard 
ANNOVAR pipeline supplied by COSMIC v68 database. All selected variants were validated by 
Sanger sequencing, first on genomic DNA and in case of splicing variants on cDNA. The potential 
pathogenicity of the identified mutations and their effects on p53 functionality was predicted by web 
tools (SIFT, http://sift.jcvi.org/; PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/; MutationTaster, 
http://www.mutationtaster.org/; HSF, http://www.umd.be/HSF; NNSplice, 
http://www.fruitfly.org/seq_tools/splice.html) and by protein structural bioinformatics analysis (NCBI, 
http://www.ncbi.nlm.nih.gov/protein/; PDB, http://pdb.org; UniProt, http://www.uniprot.org; PFAM, 
http://pfam.sanger.ac.uk). The main clinical and molecular parameters of the selected B-CLL patients 
are reported in Table 4. 
For the in vitro assays, B-CLL patients’ cells were cultured in RPMI-1640 medium containing 
10% FBS, L-glutamine and Penicillin/streptomycin (all from Gibco, Grand Island, NY) and used 
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within the first 48 hours of cultures. The p53wild-type B leukemic cell lines EHEB, JVM- 2, JVM-3, the 
p53mutated B lymphoblastoid leukemic cell lines MAVER, MEC-1 and MEC-2 and the p53null HL-60 
leukemic cell line were all purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH, Braunschweig, Germany). The p53wild-type B leukemic cell lines, MAVER and HL-
60 cell lines were routinely cultured in RPMI-1640, whereas MEC-1 and MEC-2 were maintained in 
IMDM, all supplemented with 10% FBS, L-glutamine and Penicillin/streptomycin (all from Gibco). 
 
Culture treatments, assessment of cell viability, apoptosis, cell cycle profile and 
senescence 
For in vitro treatments with DCA (Sigma-Aldrich, St Louis, MO), used either alone or in 
combination with Nutlin-3 (Cayman Chemicals, Ann Arbor, MI), cells were seeded at a density of 
1x106 cells/ml and cultured under normoxic conditions. At different time points after treatment, cell 
viability was examined by Trypan blue dye exclusion and MTT (3-(4,5-dimethilthiazol- 2yl)-2,5-
diphenyl tetrazolium bromide) colorimetric assay (Roche Diagnostics Corporation, Indianapolis, IN) 
for data confirmation. Levels of apoptosis were quantified by Annexin V-FITC/ propidium iodide (PI) 
staining (Immunotech, Marseille, France) followed by analysis using a FACSCalibur flow cytometer 
(Becton-Dickinson, San Jose, CA). To avoid non-specific fluorescence from dead cells, live cells 
were gated tightly using forward and side scatter. The cell cycle profile was analyzed by flow 
cytometry after 5-bromodeoxyuridine (BrdU) incorporation. Briefly, leukemic cells were incubated 
with 50 μM BrdU (Sigma-Aldrich) at 37°C for 1 hour. The antibody anti-BrdU (BD Biosciences 
Pharmingen, San Diego, CA) was bound to BrdU incorporated into neosynthesized DNA and the 
complex was detected by FITC conjugated secondary antibody (Immunotech). Cells were then 
stained with PI (50 μg/mL) and analyzed by flow cytometry. Senescence was assessed under light 
microscope by senescence-associated β-galactosidase (SA-β-gal) staining, using a specific kit 
(Abcam, Cambridge, UK) and following the manufacturer’s instructions. 
 
Assessment of mitochondrial alterations 
Mitochondrial activity was evaluated staining cells with MitoTracker® GreenFM (Molecular 
Probes, Inc., Eugene, Oregon), which passively diffuses across the plasma membrane and 
accumulates in active mitochondria. Briefly, at different time points, cells were incubated with pre-
warmed MitoTracker staining solution (obtained diluting MitoTracker® GreenFM in serum-free 
medium to a final concentration of 25 nM) for 30 minutes at 37°C. Cells were then washed with PBS 
(Gibco) and analyzed by flow cytometry. 
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The presence of morphological signs characteristic of mitochondrial alteration, such as 
mitochondrial fragmentation and cristae remodeling, were analyzed by transmission electron 
microscopy. Mitochondrial activity was evaluated by measuring the cellular ATP production. Briefly, 
ATP concentration was determined using the ATP Assay KIT (Abcam) in cell lysates of untreated 
and DCA treated cultures at different time points. Measurements were performed with the 
colorimetric method, following the manufacturer’s instructions. ATP contents were normalized per 
number of cells. 
 
Western blot analyses  
For Western blot analysis, cells were lysed and protein determination was performed by 
using the BCA Protein Assay (Thermo Scientific, Rockford, IL). Samples were supplemented with 
loading buffer (250 mM Tris pH 6.8, 2% SDS, 10% glycerin, 4% beta-mercaptoethanol, 1% 
bromophenol blue) and boiled for 2 minutes. Equal amounts of protein for each sample were 
migrated in SDS-polyacrylamide gels and blotted onto nitrocellulose filters. The following Abs were 
used: anti-p53 (DO-1), anti-MDM2 (SMP14), anti-p21 (C-19), anti- PUMAα/β (H-136), anti-PARP-1 
(H-250) and anti- Bax (2D2) purchased from Santa Cruz Biotechnology (Santa Cruz, CA); anti-
Phospho-p53 (Ser15) and anti- Phospho-p53 (Ser392) from Cell Signaling Technology (Danvers, 
MA); anti-tubulin from Sigma-Aldrich. After incubation with anti-mouse or anti-rabbit IgG horseradish 
peroxidase-conjugated secondary Abs (Sigma-Aldrich), specific reactions were revealed with the 
ECL Lightning detection kit (Perkin Elmer, Waltham, MA). Densitometry values for Western blot were 
estimated by the ImageQuant TL software (GE Healthcare, Buckinghamshire, UK) and were 
expressed as arbitrary units (a.u.). Multiple film exposures were used to verify the linearity of the 
samples analyzed and to avoid saturation of the film. 
 
Bi-dimensional gel electrophoresis (2-DE) and immunoblotting 
For bi-dimensional gel electrophoresis, protein extraction was performed by adding 150 μl of 
lysis buffer (5M urea, 2M tiourea, 2% CHAPS, 2% Zwittergent detergent; all from Calbiochem, San 
Diego, CA) with protease inhibitors (Complete, mini EDTA-free mixture, Roche Applied Science, 
Milan, Italy) to the cell pellets. Lysates were sonicated for 3 min, and 250 units of benzonase 
endonuclease (Novagen, San Diego, CA) were added to each sample and incubated for 40 minutes 
at room temperature on rotary shaker. Cell debris were removed by centrifugation at 13000 x g for 
10 minutes, 15°C. The supernatants were aliquoted and stored at −80°C. Protein concentration was 
measured with a modified Bradford method (BioRad, Milan, Italy). Protein extracts (30 μg) from each 
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sample were diluted to a final volume of 125 μl in the rehydration solution (5M urea, 2M thiourea, 2% 
CHAPS, 2% Zwittergent, 100 mM DeStreak, 0.5% IPG buffer pH 3–10 linear; all from GE 
Healthcare) and then applied on immobilized pH 3–10 linear gradient strips, 7 cm (IPG strips, GE 
Healthcare). Briefly, IPG strips were hydrated on an IPGphor apparatus (GE Healthcare) for 16 h at 
30 V/h and then focused for 26 h until 50,000 V-h. After the first-dimension run, proteins were 
reduced by LDS Sample Buffer (Life Technologies, Carlsbad, CA) containing 60 mM DTT (GE 
Healthcare). Proteins were alkylated by 100 mM iodoacetamide (Sigma-Aldrich). The strips were 
then embedded in 0.7% (w/v) agarose on the top of 1-mm-thick acrylamide precast gels at 10% (Life 
Technologies). After electrophoresis the proteins were transferred to nitrocellulose membrane by 
standard electroblotting and stained with MemCode™ Reversible protein stain kit (Fisher Scientific, 
Illkirch Cedex, France). After blocking with 5% dry milk in TBS-Tween20 for 1 h at room temperature, 
the membranes were probed with an anti-p53 (DO-1) antibody (Santa Cruz Biotechnology) and then 
exposed to the peroxidase-linked specie specific anti-mouse IgG (Sigma-Aldrich). The p53 positive 
proteins were visualized using chemiluminescence plus (ECL plus) Western blotting detection 
reagents (GE Healtcare). 
 
Proteomic profiling 
To perform one-dimensional gel electrophoresis (1-DE), for each experimental group 
triplicates of HL-60 cell protein extract (25 µg/replicate) were mixed with equal volume of Laemmli 
sample buffer and resolved on a NuPAGE® Novex® 4-12% Bis-Tris gel (Life Technologies). Each 
gel lane was manually cut with a sterile surgical blade into 24 bands of equal height (about 3 mm) 
and excised bands were crushed into small fragments, processed, submitted to in-gel trypsin 
digestion and peptide extractions. An aliquot of each digest (2 µl) was directly analyzed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) using a LTQ Orbitrap XL™ (Thermo 
Scientific), interfaced with a 1200 series capillary pump (Agilent Technologies Inc., Santa Clara, CA). 
For protein identification, tandem mass spectra were extracted and the charge states 
deconvoluted by BioWorks version 3.3.1 (Thermo Scientific). For each sample, the MS/MS data from 
the 24 gel bands were merged and submitted as “mgf” file to the search engine Mascot (in-house 
version 2.2.06, Matrix Science, London, UK). Scaffold (version 3_00_02, Proteome Software Inc., 
Portland, ME) was used to validate MS/MS-based peptide and protein identifications. Mascot was 
set up to search both the forward and reversed sequences of the SwissProt_57.8 database (selected 
for Humans) assuming the digestion enzyme trypsin (1 missed cleavage allowed), mass tolerance of 
1.00 Da and a parent ion tolerance of 2.0 ppm. Carbamidomethylation of cysteine was specified as a 
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fixed modification and deamidation of asparagine and oxidation of methionine were set as variable 
modifications in both search engines. Peptide identifications were accepted if they could be 
established at greater than 95.0%. Protein identifications were accepted if established at greater 
than 99.9% probability with at least 2 identified peptides. Identified proteins were quantified using 
spectral counts directly computed by Scaffold and the number of MS/MS spectra were grouped into 
“counts” associated to a specific protein. Spectral counts normalization was performed by Scaffold 8 
version 3_00_02 (Proteome Software Inc.). Subsequently estimation of differential protein 
abundance was expressed as fold-change (ratio of the averaged spectral counts in the treated cells 
to the averaged spectral counts in the untreated cells). The normalized spectral count for each 
identified protein were submitted to SIMCA-P13 software package (Umetrics, Umea, Sweden) for 
multivariate data analysis (OPLS-DA). Variables that had significant contribution to discrimination 
between groups and a significant p-value (Mann-Whitney-Wilcoxon test, p<0.05), computed using 
JMP v6 software (SAS Institute, Inc., Cary, NC), were accepted as significantly modulated proteins 
upon treatment and submitted to network analysis. Functional interpretation of the differentially 
expressed proteins highlighted by proteomics was built using the MetaCore analytical suite version 
5.3 (GeneGo, St. Joseph, MI). 
 
cDNA microarray and RT-PCR analyses 
Total RNA was extracted from cells using the Qiagen RNeasy Plus mini kit (Qiagen, Hilden, 
Germany) according to the supplier’s instructions. For the integrity measurement, 4 μl of the total 
RNA were analyzed on an Agilent Cary 60 UV-Vis Spectrophotometer (Agilent Technologies Inc). 
Microarray analyses was performed at the Qiagen SuperArray core facility 
(http://www.sabiosciences.com/customservice_pcrarray.php; SABiosciences, Qiagen, Hilden, 
Germany). To efficiently retro-transcribed mRNA, the Service Core uses the Qiagen RT² First Strand 
Kit (Qiagen); the cDNA was then hybridized with customized cDNA microarrays containing specific 
primers sets for 84 relevant apoptosis genes, cell cycle regulation genes or mitochondrial energy 
metabolism genes, plus five housekeeping genes. Analysis of gene expression was done essentially 
as described (available at http://www.sabiosciences.com/customservice_pcrarray.php). A set of 
controls present on each array enables data analysis using the ΔΔCT method of relative 
quantification, assessment of reverse transcription performance, genomic DNA contamination, and 
PCR performance. Alterations due to the treatment on the basal gene expression were determined 
as the ratio of relative gene expression compared with unstimulated cells and were considered 
significant when a > 2- or < -2 fold change of modulation was observed. The mitochondrial pathway 
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activity score was calculated using the bioinformatics tool provided by QIAGEN (available at 
http://www.sabiosciences.com/dataanalysis.php). Probability score >0,3 or <-0,3 indicates significant 
change in experimental sample as compared to control sample. 
 
RNA analyses 
Total RNA was extracted from cells using the QIAGEN RNeasy Plus mini kit (QIAGEN, 
Hilden, Germany) according to the supplier’s instructions. Once verified the quality of RNA 
preparation by agarose gel, total RNA was transcribed into cDNA, using the QuantiTect® Reverse 
Transcription kit (SABiosciences, QIAGEN). p21, MDM2, BAX, PUMA, TIGAR gene expression was 
analyzed using the SYBR Green-based real-time quantitative polymerase chain reaction (RT qPCR) 
detection method with SABiosciences RT2 Real- TimeTM Gene expression assays, which include 
specific validated primer sets and PCR master mix (SABiosciences). All samples were run in 
triplicate using the real-time thermal analyzer Rotor-GeneTM 6000 (Corbett, Cambridge, UK). 
Expression values were normalized to the housekeeping gene POLR2A amplified in the same 
sample. 
 
Transfection experiments 
A pool of three specific small interfering RNA (siRNA) for each gene was resuspended in 
nuclease-free sterile water. Leukemic cells (2x106 cells/0.1 ml) were mixed with either 1 μg of control 
enhanced green fluorescence protein (EGFP) plasmid or 3 μg of small interfering RNA (siRNA) 
cocktails, transferred to a 2.0-mm electroporation cuvette and nucleofected with the nucleofector kit 
V (Lonza Cologne AG, Cologne, Germany) using the nucleofector device (Amaxa Nucleofector II 
apparatus, Lonza). After electroporation, cells were immediately transferred to a complete medium 
and cultured at 37°C until analysis. Transfection efficiency was monitored in each experiment by 
scoring the percentage of EGFP-positive cells by flow cytometry analysis. For specific gene knock-
down, siRNAs were designed and manufactured by Ambion® (Life Technologies) according to the 
current guidelines for effective gene knock-down by this method. Negative control siRNA consisted 
of a 19 bp-scrambled sequence with 3’ dT overhangs (Ambion’s Silencer negative control siRNA). 
The Ambion’s Silencer negative control siRNA sequence has no significant homology to any known 
gene sequences from human and it has been previously tested for the lack of non-specific effects on 
gene expression. 
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Statistical analysis and assessment of the effect of combination treatment 
Descriptive statistics were calculated. For each set of experiments (ie, assays for cell 
cytotoxicity/functionality and RT-analysis), values were reported as means±standard deviation (SD). 
The results were analyzed by using the Mann-Whitney rank-sum test and statistical significance was 
defined as p<0.05. All statistical analyses were performed with SPSS Statistic 20 software (SPSS 
Inc., Chicago, IL). In order to investigate the effect of DCA+Nutlin-3 combination, leukemic cells were 
then treated with serial doses of DCA (range 3-30 mM) or Nutlin-3 (range 1-10 microM), individually 
or in combination using a constant ratio (DCA:Nutlin-3). Results were analyzed with the method of 
Chou and Talalay to determine whether combined treatment yields greater effects than expected 
from summation alone: a combination index (CI) of 1 indicates an additive effect, while a CI below 1 
indicates synergism. For this purpose cell viability data were analyzed with the CalcuSyn software 
(Biosoft, Cambridge, UK) and reported either as CI values or as dose-effect curves directly drawn by 
the CalcuSyn software. Proteomics data were analyzed by both multivariate and univariate 
approaches. The normalized spectral counts for each identified proteins were submitted to SIMCA-
P13 software package (Umetrics, Umea, Sweden) for multivariate data analysis. Variables were 
scaled using Pareto scaling and data were analyzed by orthogonal partial least-squares discriminant 
analysis (OPLS-DA). S-plots were calculated to visualize the relationship between covariance and 
correlation within the OPLS-DA results. Variables that showed significant contribution to 
discrimination between groups and a significant change in their expression (Mann-Whitney-Wilcoxon 
test, p<0.05), were accepted as significantly modulated proteins upon treatment and submitted to 
network analysis.  
Analysis of the anti-leukemic activity of sodium dichloroacetate 
26 
Results 
 
 
 
 
DCA promotes cytotoxicity in primary B-CLL patient derived cells, but not in normal 
peripheral blood cells 
 
The first group of experiments was designed to investigate whether DCA promoted 
cytotoxicity in leukemic cells. For this purpose, the effect of DCA was comparatively analyzed on 
primary PBMC derived from B-CLL patients (n=22; Table 2) and from healthy blood donors (n=10). 
Treatment with DCA, used in the range of 1-30 mM for up to 48 hours, exhibited a dose- and time-
dependent cytotoxicity, resulting in significant reduction of leukemic cell viability with respect to the 
untreated cultures, at concentrations ≥3 mM in B-CLL patient cell samples (Figure 3A). The IC50 
(50% inhibition concentration) mean values (±SD) of cytotoxicity of DCA in B-CLL patient samples 
were 22±11 mM and 12±6 mM at 24 and 48 hours of treatment, respectively (Figure 3B). On the 
other hand, PBMC obtained from healthy donors were significantly less susceptible to DCA 
cytotoxicity as compared to primary B-CLL cells, with IC50 mean values (±SD) of cytotoxicity of 
122±49 mM and 93±52 mM at 24 and 48 hours of treatment (Figure 3A-B), clearly showing that 
normal PBMC were completely resistant to DCA effects at concentrations ≤10 mM. Thus, in line with 
previous data obtained in solid tumor cell models [95-104] and multiple myeloma [105], we have 
demonstrated for the first time that DCA promoted a significant cytotoxicity also in primary B-CLL 
samples but not in normal PBMC. 
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Table 2. Clinical and laboratory features of the B-CLL patients involved in the study 
 
FCR, fludarabine, cyclophosphamide, rituximab; Chl, chlorambucil; mut, mutated; unmut, unmutated; WT, wild-type; na, not available. 
 
  
Patient 
# 
Age/Sex 
Rai 
stage 
WBC count 
(x103/mL) 
%CD38+ 
cells 
ZAP-70 IgVH status 
Cytogenetic 
abnormalities 
(FISH) 
p53 status Therapy 
1 77/M 0 81.4 2 2 mut del13q omoz. WT none 
2 85/F 1 54 1 5 mut tri12 WT Chl 
3 68/M 0 82.9 3.3 21 mut del13q na none 
4 79/F 1 47.9 2.9 na na na na FCR 
5 75/F 1 56.6 1.9 8 mut na na none 
6 73/F 1 95 2.1 50 mut del13q WT Chl 
7 75/M 0 96.8 1.1 30 mut del13q WT none 
8 79/F 0 54.8 6.3 1.8 unmut del11q/del13q omoz. WT F 
9 66/M 0 108.1 0 24.3 unmut del13q WT FCR 
10 56/M II 128.3 1.2 60 unmut Normal WT FCR 
11 82/F 0 23.3 50.9 6.4 mut Normal WT none 
12 55/F 0 9.3 77.9 13 unmut del11q WT none 
13 65/M 0 25.3 6 27.1 mut Normal WT none 
14 75/M 0 23.1 21 19.7 unmut del13q WT none 
15 73/M 0 27.7 10.3 10.2 mut del13q WT none 
16 71/F 0 14.2 0 20.6 na del13q WT none 
17 75/M 0 59.7 6.8 0.3 mut del13q WT none 
18 55/F 0 86.5 7 7.4 unmut del13q WT none 
19 77/M IV 100 15.4 72.1 unmut tris 12 WT Chl 
20 51/F 0 105 2.8 20 unmut del11q/del13q WT none 
21 87/F II 121 58.5 2.4 unmut del13q/tris 12 WT Chl 
22 72/M II 21.2 55.2 na unmut del13q/tris 12 WT none 
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Figure 3. Comparative evaluation of cell viability in response to DCA in B-CLL patient leukemic cells and 
PBMC from healthy human blood donors. B-CLL patient cell samples (n=22) and PBMC from healthy blood donors 
(n=10) were exposed to serial doses of DCA (range 1-30 mM) as indicated. In A, cell viability was analyzed at 24 
and 48 hours of treatment and was calculated as percentage of untreated cultures set to 100%. Data are reported 
as mean values ±SD. The asterisk indicates p<0.05 with respect to the untreated cultures. In B, IC50 values are 
reported as mean value ±SD. 
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DCA activates the p53 pathway in p53wild-type B leukemic cell lines 
 
Most B-CLL at diagnosis are p53wild-type [29,30], as the primary B-CLL samples analyzed in 
this study, and it is noteworthy that previous studies on solid tumors have implicated the p53 
pathway in mediating the anti-tumoral activity of DCA [96,97,138]. Therefore, in order to investigate 
the potential involvement of p53 in mediating the anti-leukemic activity of DCA, we next performed a 
series of experiments on three p53wild-type B leukemic cell lines (EHEB, JVM-2 and JVM-3). As shown 
in Figure 4A, treatment with DCA resulted in a dose-dependent reduction of cell viability in all the 
p53wild-type B leukemic cell lines tested; accordingly the IC50 values varied from 30.9 to 46.5 mM at 24 
hours of treatment and from 13.8 to 19.5 mM at 48 hours of treatment, comparable to those of 
primary B-CLL cells (Figure 3B). Flow cytometric analysis of these leukemic cell cultures 
demonstrated that treatment with DCA induced early accumulation in G1 phase of the cell cycle 
(Figure 4B) and promoted apoptosis in all leukemic cell lines (Figure 4C). The cytotoxic effects of 
DCA on the B cell lines were coupled to the ability of DCA to reduce the mitochondrial membrane 
potential (Figure 4D). 
 
A 
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Figure 4. Cytotoxicity induced by DCA in B leukemic cell lines. The p53wild-type (EHEB, JVM-2, JVM-3) B 
leukemic cell lines were exposed to DCA before analysis of cell toxicity. In A, cell viability in response to serial 
doses of DCA (range 1-30 mM), was calculated at both 24 and 48 hours of treatment as percentage with respect to 
the control vehicle cultures (set to 100% for each cell line). In B, cell distribution in the different phases of cell cycle 
was calculated from the flow cytometry dot plots after BrdU/PI staining and expressed as percentage of the total 
population. Representative cell-cycle profiles of cells, either left untreated or treated with serial doses of DCA, 
analyzed by flow cytometry are shown. In the right panel, the rectangles represent the cells in G0/G1, S, G2/M 
phases of the cell cycle. In C, the percentage of apoptotic cells was determined by flow-cytometry after Annexin 
V/PI staining (upper panel). A representative flow cytometric analysis of apoptosis, validated also by Western blot 
analysis of PARP cleavage, is shown (lower panels). In D, to measure changes in the mitochondrial membrane 
m), upon treatment with DCA for 24h cells were stained with MitoTracker solution and analyzed by flow 
cytometry. Median values of mitochondrial MitoTracker fluorescence and representative histograms are shown. In 
A, C and D, data are reported as the mean±SD of results from three independent experiments. In A and D, the 
asterisk indicates p<0.05 with respect to the untreated cultures of each cell line. 
 
Based on these evidences, documenting the anti-proliferative/pro-apoptotic activity of DCA 
in B leukemic cells, we next assessed the effect of DCA treatment on the expression of p53 in the 
EHEB, JVM-2, JVM-3 cell lines by two-dimensional electrophoresis and immunoblotting, which 
allows separation of proteins based on their molecular weight (MW) and isoelectric point (pI). As 
shown in Figure 5A, two-dimensional electrophoresis revealed the presence of the full-length p53 
(~53 kDa, pI 6-7.3) beside a group of spots below the 53 kDa (~40 kDa, pI 5.5-6.5) in the untreated 
cultures. Upon DCA treatment for 24 hours, we observed a slight increase in the full-length p53 
protein in the EHEB cell line and, of note, the appearance of a series of isoforms above the 53 kDa 
in all the cell lines, suggestive of p53 post-translational modifications. In this respect, in Western blot 
assay we have documented that DCA dose-dependently induced p53 phosphorylation in Ser15 and 
Ser392 (Figure 5B). To test the hypothesis of functional activation of p53 upon exposure to DCA, in 
parallel experiments we have analyzed the levels of a subset of p53 transcriptional targets involved 
in promoting cell cycle arrest (p21), modulation of apoptosis (MDM2, Bax, PUMA) or metabolism 
(TIGAR) by RT-PCR. As shown in Figure 3C, DCA variably but significantly (>2 fold) increased the 
mRNA levels of MDM2, p21, PUMA and TIGAR in all leukemic cell lines investigated, while no 
significant modulation of BAX mRNA was observed.  
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Figure 5. Activation of p53 pathway by DCA in p53wild-type B leukemic cells. p53wild-type B leukemic EHEB, 
JVM-2 and JVM-3 cells were left untreated or treated with DCA for 24 hours. In A, cell lysates were analyzed by 
two-dimensional immunoblot. The antibody p53 (DO-1) identified a spot group corresponding to full-length p53 (~53 
kDa) and a series of p53 isoforms with a molecular weight above 53 kDa (square brackets). In B, equal amounts of 
cell lysates, obtained from EHEB cells, were analyzed for protein levels by Western blot. Tubulin staining is shown 
as a loading control. Blots representative of at least three independent experiments yielding equivalent results are 
shown. In C, transcriptional activation of p53 target genes, MDM2, p21, BAX, PUMA and TIGAR, was assessed by 
quantitative RT-PCR. mRNA levels are expressed as folds of modulation, with respect to the control untreated 
cultures set at 1. Results are reported as means±SD of six independent experiments carried out on the three 
different cell lines. 
 
DCA plus Nutlin-3 combination exhibits a potent synergistic anti-leukemic activity 
 
In the next group of experiments, we have examined the potential interaction of DCA with 
Nutlin-3, a small molecule which transcriptionally activates p53 by abolishing its interaction with its 
principal inhibitor MDM2 [139]. For this purpose, leukemic cells were treated with DCA (3-30 mM) 
and Nutlin-3 (1-10 M), used as single agents and in combination. In particular, B-CLL leukemic 
cells were treated with serial concentrations of DCA and Nutlin-3 at a constant DCA:Nutlin-3 ratio for 
data analysis by the method of Chou and Talalay. Combined treatment with DCA+Nutlin-3 resulted 
in significantly (p<0.01) greater cytotoxicity with respect to the single agents, with a synergistic effect 
both in primary B-CLL patient samples as well as in B leukemic cell lines (Figure 6A-B), as 
documented by an average Combination Index (CI) <1 (Table 3). The cytotoxicity induced by the 
combined treatment with DCA+Nutlin-3 was mainly due to the increase of the degree of apoptosis 
with respect to the treatment with DCA or Nutlin-3 used alone (Figure 6C).  
B 
C 
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Figure 6. Cytotoxicity by DCA and Nutlin-3 used alone or in combination in p53wild-type B leukemic cells 
and B-CLL patient leukemic cells. p53wild-type B leukemic EHEB, JVM-2 and JVM-3 cells and B-CLL patient leukemic 
cells were exposed to serial doses of DCA or Nutlin-3 used either alone or in combination, with a fixed ratio, for 24 
hours. Dose-effect plots, to determine drug efficacy, are shown for each cell line (A) and for representative B-CLL 
patient samples (B). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at 
least twice in duplicate. In C, induction of apoptosis in B-CLL patient leukemic cells was calculated as percentage 
of Annexin V/PI cells. Data are reported as mean±SD of results from three independent experiments. A 
representative flow cytometric analysis of apoptosis in a primary B-CLL sample is shown. The asterisk indicates 
p<0.05 with respect to cultures treated with either DCA or Nutlin-3 alone. 
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Table 3. Combination index values for the effect of DCA plus Nutlin-3 on viability of B-CLL patient cells 
and p53wild-type B cell lines 
 
Cells ED50 ED75 ED90 Average CI 
Patient #1 0.33 0.29 0.26 0.29 
Patient #2 0.18 0.03 0.01 0.07 
Patient #3 0.37 0.38 0.40 0.38 
Patient #4 0.31 0.39 0.52 0.41 
Patient #5 0.43 0.37 0.34 0.38 
Patient #6 0.37 0.31 0.30 0.33 
Patient #7 0.37 0.32 0.29 0.33 
Patient #8 0.06 0.16 0.46 0.23 
Patient #9 0.20 0.56 1.61 0.79 
Patient #10 0.67 0.95 1.36 0.99 
Patient #11 0.20 0.27 0.37 0.28 
Patient #12 0.15 0.29 0.68 0.37 
Patient #13 0.05 0.06 0.09 0.07 
Patient #14 0.19 0.02 0.004 0.07 
Patient #15 0.35 0.1 0.03 0.16 
Patient #16 0.24 0.04 0.007 0.10 
Patient #17 0.11 0.30 0.80 0.40 
Patient #18 0.45 0.43 0.42 0.43 
Patient #19 0.01 0.08 0.58 0.22 
Patient #20 0.09 0.07 0.05 0.07 
Patient #21 0.22 0.24 0.29 0.25 
Patient #22 0.19 0.13 0.09 0.14 
EHEB 0.39 0.49 0.66 0.51 
JVM-2 0.16 0.11 0.13 0.13 
JVM-3 0.06 0.08 0.11 0.08 
ED indicates effect dose. The average combination index (CI) values were calculated from ED50, ED75, and ED90. 
 
 
Role of p21 induction in DCA and DCA+Nutlin-3 induced cytotoxicity in leukemic cells 
 
With respect to DCA treatment, Nutlin-3 induced a much more potent accumulation of both 
p53 and its molecular targets MDM2 and p21 in p53wild-type leukemic cells, as documented by 
Western blot analysis performed on total cell lysates (Figure 7A). The combination of DCA+Nutlin-3 
did not result in a further accumulation of p53 protein with respect to Nutlin-3 alone while it promoted 
a greater induction of MDM2 and p21 proteins with respect to Nutlin-3 alone (Figure 7A). 
Interestingly, the combination of Nutlin-3+DCA significantly (p<0.05) enhanced the induction of 
MDM2 and p21 at the mRNA level, in both B leukemic cell lines and primary B-CLL patient samples, 
but not in normal PBMC (Figure 7B). Of note, the synergistic transcriptional induction of p53-target 
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genes by DCA+Nutlin-3, documented in leukemic cells but not in normal PBMC, correlated with the 
lower cytotoxicity of DCA+Nutlin-3 in these cells (Figure 7C). 
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Figure 7. Activation of p53 pathway by DCA+Nutlin-3 combination. In A, equal amounts of cell lysates, 
obtained from EHEB cells treated for 24 hours with DCA and Nutlin-3, used either alone or in combination, were 
analyzed for protein levels by Western blot. Tubulin staining is shown as a loading control. Blots representative of 
at least three independent experiments yielding equivalent results are shown. After densitometric analyses, protein 
levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control 
untreated cultures set at 1. In B and C, p53wild-type B leukemic cell lines, B-CLL patient leukemic cells and PBMC 
from healthy human blood donors respectively were exposed for 24 hours to DCA and Nutlin-3, used either alone 
or in combination, as indicated. In B, the expression levels of p53 target genes were assessed by quantitative RT-
PCR and results were indicated as folds of modulation with respect to the control untreated cultures set at 1. Data 
are reported as mean±SD of results from independent experiments. The asterisk indicates p<0.05 with respect to 
cultures treated with either DCA or Nutlin-3 alone. In C, cell viability was analyzed at 24 and 48 hours of treatment 
and was calculated as percentage of untreated cultures set to 100%. Data are reported as mean values ±SD. 
 
 
The data illustrated above demonstrated that DCA+Nutlin-3 strongly synergized both in 
promoting leukemic cytotoxicity as well as in inducing p53 transcriptional activity; it was particularly 
noteworthy that one of the genes up-regulated in response to DCA±Nutlin-3 was p21. In this respect, 
a recent study has demonstrated that a strong induction of p21 by genotoxic agents was predictive of 
better prognosis in B-CLL [140]. Conversely, a lack of induction of p21 was observed in B-CLL 
patient samples showing a worse prognosis even in the presence of an integral activation of p53 
[40]. Therefore, in order to functionally elucidate the role of p21 in mediating the anti-leukemic 
activity of DCA+Nutlin-3, we utilized siRNAs to attenuate p21 expression. The knock-down of p21 
expression was demonstrated by quantitative RT-PCR, documenting a significant reduction of p21 
mRNA in EHEB cells, transfected with a cocktail of p21 specific siRNAs, both at baseline as well as 
after DCA+Nutlin-3 treatment (Figure 8A). Of note, in EHEB samples in which p21 expression was 
knocked-down by transfection with p21 specific siRNAs, the DCA+Nutlin-3-mediated cytotoxicity was 
significantly (p<0.05) reduced with respect to either cells transfected with a scrambled control siRNA 
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or cells not transfected (Figure 8B). Overall, these experiments support a potential role of p21 in 
modulating the anti-leukemic activity of DCA+Nutlin-3.  
 
A         B 
 
 
Figure 8. Role of p21 pathway in mediating the anti-leukemic activity of DCA+Nutlin-3. EHEB cells were 
transfected with either control scrambled (scr) siRNA or p21 siRNA before treatment. In A, after transfection, 
efficiency of p21 knock-down was documented by analyzing levels of p21 mRNA by quantitative RT-PCR, in 
untreated cells and upon treatment with DCA+Nutlin-3. Results are expressed as folds of modulation with respect 
to the control cultures. In B, cultures transfected with either control scrambled (scr) siRNA or p21 siRNA were 
analyzed for cell viability upon exposure to DCA+Nutlin-3. Results are expressed as percentage with respect to the 
control vehicle cultures (set to 100%). Data are reported as means±SD. 
 
 
DCA promotes comparable cytotoxicity in p53wild-type and p53mutated B-CLL patient cells  
Since B-CLL patients characterized by p53 dysfunction have limited treatment options and 
poor overall survival [129,131,132], we then comparatively evaluated the in vitro effect of DCA 
assessed on B-CLL patient cells characterized by either p53 wild-type or harboring TP53 mutations 
(Table 4). For this purpose, upon validation of a TP53 next generation sequencing screening 
(performed on a total of 80 B-CLL patients), we selected 5 patients with p53 wild-type and 5 patients 
characterized by mutations potentially affecting p53 functionality, as predicted by web mutation 
pathogenicity prediction tools and protein structural bioinformatic analysis (Table 4 and Figure 9). B-
CLL cell cultures were exposed in vitro to DCA in a range of concentrations (1-30 mM) previously 
used by other authors in in vitro solid tumor models [101-103,105]. As documented by the IC50 
values, in vitro treatment with DCA induced a significant and progressive reduction of cell viability, 
with respect to the untreated cultures assessed at the same time points (24 and 48 hours), in all the 
primary B-CLL patient cell cultures, irrespectively of the p53 status (Table 5). 
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Table 4. Clinical and laboratory characteristics of selected B-CLL patients 
 
B-CLL Pt.# Sex Age Rai stage Therapy %CD38+ cells %ZAP-70+ 
Cytogenetic 
Abnormalities* 
IgVH status TP53 analysis (NGS) 
1 M 73 0 none 10.3 10.2 del13q mut unmut 
2 F 78 0 F 6.3 1.8 del11q/del13q omoz. unmut unmut 
3 M 63 0 FCR 0 24.3 del13q unmut unmut 
4 M 54 II FCR 1.2 60 normal unmut unmut 
5 M 77 IV Chl 15.4 72.1 tris 12 unmut unmut 
6 M 55 0 FCR 6.7 18.9 tris 12 unmut NM_000546:exon5:c.470T>A:p.V157D 
7 M 71 IV FCR 6.5 na del13q/del17p mut 
NM_000546:exon8:c.817C>T:p.R273C 
NM_000546:exon7:c.701A>G:p.Y234C  
8 M 68 IV R-Benda 16.6 8.6 del11q/del13q/del17p unmut NM_000546:exon7:c.770T>C:p.L257P 
9 M 79 II Chl 14.3 1.9 del13q/del17p unmut NM_000546:exon6:c.376-2A>G: p.Y126Tfs*44 
10 M 75 0 Chl 3.6 41.1 del13q/del17p na NM_000546:exon8:c.832C>T:p.P278S 
 
Pt., patient; NGS, next generation sequencing; mut, mutated; unmut, unmutated; na, not available; F, Fludarabine; FCR, Fludarabine-Cyclophosphamide-Rituximab; R-Benda, Rituximab-Bendamustine; Chl, 
Chlorambucil. * Cytogenetic abnormalities were evaluated by fluorescence in situ hybridization (FISH) analysis. 
 
Analysis of the anti-leukemic activity of sodium dichloroacetate 
 
39 
 
 
Figure 9. Sites of mutation in p53 in the B-CLL patients investigated. A schematic representation of the 
393 amino acid domain structure of human p53 is shown. The sites of the mutations detected in the B-CLL patients 
(Pt.#6-10) are indicated. The nomenclature follows the current HGVS recommendations for the description of 
sequence variants. 
 
Table 5. IC50 for DCA in leukemic cells 
 
Leukemic cells TP53 status 
IC50 DCA (mM) 
24 hours 48 hours 
B-CLL Pt.#1 wild-type 20.6 14.7 
B-CLL Pt.#2 wild-type 24.8 12.7 
B-CLL Pt.#3 wild-type 28.5 9.7 
B-CLL Pt.#4 wild-type 23.1 16.5 
B-CLL Pt.#5 wild-type 36.2 <1 
B-CLL Pt.#6 mutated 41.9 20.4 
B-CLL Pt.#7 mutated 32.1 15.0 
B-CLL Pt.#8 mutated 5.0 <1 
B-CLL Pt.#9 mutated 17.0 15.6 
B-CLL Pt.#10 mutated 28.1 14.8 
MAVER mutated 27.9 14.5 
MEC-1 mutated 16.2 10.4 
MEC-2 mutated 33.7 22.7 
HL-60 null 43.0 24.4 
 
Although we have previously shown that DCA activates the p53 pathway in p53wild-type B 
leukemic cells, the current set of data suggested that DCA can promotes cytotoxicity also 
independently of functional p53. Thus, to investigate the molecular mechanisms underlining DCA 
cytotoxicity in leukemic cells with dysfunctional p53, we selected three p53mutated B leukemic cell lines 
(MAVER, MEC-1, MEC-2), which exhibited a dose- and time-dependent cytotoxic response to DCA 
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(Figure 10A) with IC50 values comparable to those assessed for primary p53wild-type and p53mutated B-
CLL cells (Table 5). The ability of DCA to promote p53-independent cytotoxicity in leukemic cells was 
further supported by experiments performed on the p53null HL-60 cell line (Figure 10B).  
 
 
 
Figure 10. Cytotoxicity induced by DCA in p53mutated/null leukemic cell lines. The p53mutated B leukemic 
cell lines MAVER, MEC-1 and MEC-2 (A), as well as the p53null HL-60 cells (B), were exposed to serial doses of 
DCA (range 1-30 mM) before analysis of cell viability at both 24 and 48 hours of treatment. Dose response curves 
were derived by calculating the cell viability as percentage with respect to the untreated cultures (set to 100%). 
Data are means±SD of at least three independent experiments, each performed in duplicate (Mann-Whitney rank-
sum test; asterisks, p<0.05). 
 
The cytotoxicity induced by DCA in p53mutated/null leukemic cell lines was the result of (i) a 
cytostatic effect with the accumulation in G1 phase of the cell cycle (Figure 11A), (ii) the promotion of 
cellular senescence (Figure 11B), (iii) the induction of mitochondrial damage as documented by both 
the morphological remodelling of mitochondrial structure and the reduction in ATP synthesis (Figure 
11C), coupled to (iv) apoptosis (Figure 11D). 
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Figure 11. Effects of DCA treatment on p53mutated/null leukemic cell lines. The p53mutated B leukemic cell 
lines MAVER, MEC-1 and MEC-2, as well as the p53null HL-60 cells, were exposed to DCA (30 mM). In A, cell 
distribution in the different phases of the cell cycle was calculated from the flow cytometry dot plots after BrdU/PI 
staining and expressed as percentage of the total population. In the upper panel, data are reported as the means of 
results from at least three independent experiments (Mann-Whitney rank-sum test; asterisks, p<0.05). In the lower 
panel, representative cell cycle profiles of cultures, either left untreated or treated with DCA, analyzed by flow 
cytometry are shown. For each cytofluorimetric analysis, the rectangles represent the cells in G0/G1, S, G2/M 
phases of the cell cycle. In B, cell senescence was visualized by SA-β-gal staining. Representative fields observed 
under light microscope are shown (arrows, senescent cells); cells with positive staining for SA-β-gal were quantified 
by counting a total of 1000 cells for each culture condition. Data are expressed as means±SD of six different fields 
in three independent experiments (Mann-Whitney rank-sum test; asterisks, p<0.05). In C, assessment of 
mitochondrial alterations was carried out by morphological and functional analyses. Transmission electron 
microscopy images of cytosolic regions show mitochondria (asterisks; original magnification 31,500X) with either 
normal morphology or cristae remodeling, in untreated or DCA treated cultures, respectively. Representative fields 
of three independent experiments are shown. In the lower panel, cellular ATP levels were quantified in cell lysates 
at the indicated time points. Data are reported as percentage with respect to the untreated cultures (set to 100%) 
and are means±SD of three independent experiments, each performed in duplicate (Mann-Whitney rank-sum test; 
asterisks, p<0.05). In D, the percentage of apoptotic cells was determined by flow cytometry after Annexin V/PI 
staining. Representative experiments are shown. In the graph, data are reported as the means±SD of results from 
at least three independent experiments (Mann-Whitney rank-sum test; asterisks, p<0.05).  
 
 
DCA effects on HL-60 apoptosis, cell cycle and mitochondrial energy metabolism 
transcriptomic profile 
 
To address the p53-independent mechanism of DCA action at transcriptional level, we 
performed a gene expression profile of HL-60 cells exposed to DCA 30mM for 24h in comparison to 
untreated cells. For this purpose, RNA was analyzed by cDNA microarray for a set of genes, which 
can be sub-grouped according to their cellular function in apoptosis, cell cycle and mitochondrial 
energy metabolism-related genes. The analysis evidenced a general up-modulation of apoptotic and 
cell cycle related-genes and a down-modulation of mitochondrial energy metabolism genes. Genes 
that were significantly differentially modulated (above the cutoff of 2 fold of induction or below the 
cutoff of -2 fold of reduction) for each set are reported in Tables 6-8. Among the group of apoptotic 
genes, DCA induced prevalently the transcription of anti-apoptotic genes, such as BCL2-related 
proteins (BAG3, BCL2, BCL2A1), the inhibitory factor XIAP and the decoy receptor for TRAIL 
TNFRSF11B. In parallel, the cell cycle transcriptomic profile is consistent with the anti-mitotic 
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response of HL-60 cells upon DCA treatment, as evidenced in Figure 11A. Indeed, the microarray 
analysis revealed the activation of two important genes involved in cell cycle arrest, namely CDKN1A 
(p21) and CDK5R1 [141]. 
 
Table 6. Apoptosis-related genes differentially modulated in HL-60 cells after DCA treatment 
Description Symbol Fold Regulation 
BCL2-associated athanogene 3 BAG3 8,05 
Baculoviral IAP repeat containing 3 BIRC3 1,50 
B-cell CLL/lymphoma 2 BCL2 1,97 
BCL2-antagonist/killer 1 BAK1 1,65 
BCL2-like 11 (apoptosis facilitator) BCL2L11 1,60 
BCL2-related protein A1 BCL2A1 2,64 
Bifunctional apoptosis regulator BFAR 1,53 
CASP2 and RIPK1 domain containing adaptor with death domain CRADD -1,52 
CASP8 and FADD-like apoptosis regulator CFLAR 1,76 
CD27 molecule CD27 2,67 
CD40 molecule, TNF receptor superfamily member 5 CD40 1,95 
CD70 molecule CD70 2,37 
Growth arrest and DNA-damage-inducible, alpha GADD45A 2,00 
Lymphotoxin beta receptor (TNFR superfamily, member 3) LTBR 1,81 
Tumor necrosis factor TNF 2,53 
Tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 1,82 
Tumor necrosis factor receptor superfamily, member 11b TNFRSF11B 5,61 
Tumor necrosis factor receptor superfamily, member 9 TNFRSF9 3,12 
X-linked inhibitor of apoptosis XIAP 2,04 
Data report genes differentially modulated (above the cutoff of 1.5 fold of induction or below the cutoff of -1.5 fold of reduction) after 
DCA 30mM treatment in HL-60 cells. Genes significantly up-modulated (above the cutoff of 2 fold of induction) or down-modulated 
(below the cutoff of -2 fold of reduction) are indicated in boldface type. 
 
 
Table 7. Cell cycle-related genes differentially modulated in HL-60 cells after DCA treatment 
Description Symbol Fold Regulation 
Ataxia telangiectasia mutated ATM 1,50 
Cell division cycle 34 homolog (S. cerevisiae) CDC34 2,04 
Cyclin G2 CCNG2 1,73 
Cyclin-dependent kinase 5, regulatory subunit 1 (p35) CDK5R1 2,21 
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 3,42 
Cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B 1,50 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) CDKN2A 1,81 
Growth arrest and DNA-damage-inducible, alpha GADD45A 2,00 
Mdm2 p53 binding protein homolog (mouse) MDM2 1,75 
Minichromosome maintenance complex component 2 MCM2 -1,50 
RAD51 homolog (S. cerevisiae) RAD51 -1,89 
SERTA domain containing 1 SERTAD1 2,62 
S-phase kinase-associated protein 2 (p45) SKP2 -1,73 
Data report genes differentially modulated (above the cutoff of 1.5 fold of induction or below the cutoff of -1.5 fold of reduction) after 
DCA 30mM treatment in HL-60 cells. Genes significantly up-modulated (above the cutoff of 2 fold of induction) or down-modulated 
(below the cutoff of -2 fold of reduction) are indicated in boldface type. 
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Table 8. Mitochondrial energy metabolism-related genes differentially modulated in HL-60 cells after DCA 
treatment 
Description Symbol Fold Regulation 
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) ATP5G1 -1,54 
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) ATP5G2 -1,65 
Cytochrome c oxidase subunit Vic COX6C 1,95 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13kDa NDUFA5 -3,69 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa NDUFB6 -2,05 
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5kDa NDUFC2 -1,56 
Succinate dehydrogenase complex, subunit A, flavoprotein (Fp) SDHA -1,83 
Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa UQCRQ -1,65 
Data report genes differentially modulated (above the cutoff of 1.5 fold of induction or below the cutoff of -1.5 fold of reduction) after 
DCA 30mM treatment in HL-60 cells. Genes significantly up-modulated (above the cutoff of 2 fold of induction) or down-modulated 
(below the cutoff of -2 fold of reduction) are indicated in boldface type. 
 
As to regard the mitochondrial energy metabolism array data, DCA induced the down-
modulation of two accessory subunits of the mitochondrial NADH dehydrogenase complex (NDUFA5 
and NDUFB6) and of the succinate dehydrogenase complex subunit A (SDHA) genes, suggesting a 
slowing effect on the electrons’ transfer along the mitochondrial membrane respiratory chain.  
 
Table 9. Mitochondrial pathway activity signature genes expression in HL-60 cells after DCA treatment 
Description Symbol Fold Regulation 
Arrestin domain containing 3 ARRDC3 1,57 
Ankyrin repeat and SOCS box containing 1 ASB1 nc 
Cytochrome b-561 domain containing 1 CYB561D1 nc 
DnaJ (Hsp40) homolog, subfamily B, member 1 DNAJB1 nc 
Endothelin 1 EDN1 nc 
Growth arrest and DNA-damage-inducible, beta GADD45B nc 
Heat shock 70kDa protein 1A HSPA1A -1,94 
Heat shock 70kDa protein 1B HSPA1B 1,93 
Low density lipoprotein receptor-related protein 5-like LRP5L nc 
Polycistronic_H1_3 MitoH1 nc 
Polycistronic_H2_200_12106_1 MitoH2_12106 nc 
Polycistronic_H2_200_14573_3 MitoH2_14573 -1,51 
Polycistronic_H2_200_4162_1 MitoH2_4162 -1,57 
Polycistronic_H2_200_5726_3 MitoH2_5726 nc 
RNU11 RNU11 nc 
Solute carrier family 25 (mitochondrial phosphate carrier), member 25 SLC25A25 nc 
Data presented in boldface type indicate genes significantly up-modulated (above the cutoff of 2 fold of induction) or down-modulated 
(below the cutoff of -2 fold of reduction). nc, not significant fold change in gene expression. 
 
Mitochondrial dysfunction at transcriptional level can be reliably determined since the array 
includes 16 experimentally derived signature biomarker genes which, along with classification 
algorithms, are used to generate the activity score (Table 9). The calculation of this parameter did 
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not reveal any detectable change in mitochondrial pathway activity at gene expression level 
(pathway activity score upon DCA treatment = 0,062). 
 
DCA induces the transcription of p21 in both p53wild-type and p53mutated/null leukemic 
cells 
In the next set of experiments, we have investigated the mRNA levels of p21, whose in vitro 
induction represents a positive prognostic marker of response to therapy [140]. Surprisingly, DCA 
was equally effective in increasing the transcription levels of p21 in both primary p53wild-type and 
p53mutated B-CLL leukemic cells (Figure 12A). The induction of p21 was confirmed at the protein level 
by Western blot analysis. Moreover, DCA significantly increased the steady-state mRNA levels in all 
the p53mutated B cell lines (MAVER, MEC-1 and MEC-2) as well as in p53null HL-60 (Figure 12A), thus 
confirming the ability of DCA to induce p21 expression independently of the presence of p53. In 
parallel, a confirmation of the lack of functional p53 transcriptional activity in both p53mutated primary 
B-CLL cells and p53mutated MAVER, MEC-1 and MEC-2 cell lines as well as in p53null HL-60 was 
provided by the use of Nutlin-3. Indeed, while Nutlin-3 (10 µM) potently induced p21 transcription in 
primary p53wild-type B-CLL cells, it did not promote any modulation of p21 mRNA over the baseline in 
both primary p53mutated B-CLL patient samples and p53mutated/null leukemic cell lines (Figure 12B), thus 
confirming the p53-independent activation of p21 by DCA in these cell models. 
A 
 
B 
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Figure 12. Induction of p21 by DCA in p53mutated/null leukemic cells. Levels of p21 were analyzed by 
quantitative RT-PCR in the p53wilde-type and p53mutated B-CLL patient samples, as well as in the p53mutated B leukemic 
cell lines (MAVER, MEC-1 and MEC-2) and in the p53null HL-60 cells. In A, levels of p21 modulation upon 24 hours 
of treatment with DCA (30 mM) are shown. Representative western blot results documenting induction of p21 
protein by DCA in 2 B-CLL patient samples are shown in the insets. In B, the same cell cultures were exposed for 
24 hours to Nutlin-3 (10 M) before measurement of p21 levels. In parallel, as a positive control, p21 induction by 
Nutlin-3 was assessed in a p53wild-type B-CLL sample. In A and B, mRNA levels are expressed as fold of modulation 
with respect to the control untreated cultures set at 1. Results are reported as means±SD of at least three 
independent experiments, performed in duplicate, carried out on each leukemic sample. 
 
 
DCA effects on HL-60 proteomic profile 
To gain insight into the p53-independent induction of p21 by DCA, we adopted a proteomic 
approach using the HL-60 p53null leukemic model in order to rule out any potential interference by 
mutated p53 protein. For this purpose, we used a 1-DE gel approach for protein pre-fractionation 
integrated into a typical LC-MS/MS workflow for protein identification, performed as previously 
described [142]. A label-free approach (spectral counting) was then used for relative protein 
abundance quantification. Overall, our proteomic analysis identified 727 proteins in the total lysate of 
untreated and DCA treated HL-60 cells. According to statistical tests, HL-60 exposed to DCA 30mM 
for 24 hours exhibited a significant difference (at least 3-fold) in the abundance of 17 proteins 
compared to the untreated counterpart, with 10 up-regulated proteins and 7 down-regulated proteins 
(Tables 10 and 11). 
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Table 10. Differential expression data (as normalized spectral counts) for each identified protein whose abundance was significantly altered in HL-60 cells by DCA treatment 
 
Protein name UniprotKB 
HL-60 Untreated HL-60 DCA30mM 
Fold regulationg 1Ra 
NSCd 
2Rb 
NSCd 
3Rc 
NSCd 
Average NSC SDe %CVf 
1Ra 
NSCd 
2Rb 
NSCd 
3Rc 
NSCd 
Average 
NSC 
SDe %CVf 
ADP/ATP translocase 2 (ANT2) P05141 26 35 37 32.67 5.86 17.94 1 1 1 1.00 0.00 0.00 -32.67 
ADP-ribosylation factor 4  P18085 1 1 1 1.00 0.00 0.00 6 6 5 5.67 0.58 10.19 5.67 
ADP-ribosylation factor 5 P84085 1 1 1 1.00 0.00 0.00 8 8 6 7.33 1.15 15.75 7.33 
Asparagine-tRNA ligase, cytoplasmic  O43776 4 4 5 4.33 0.58 13.32 17 20 21 19.33 2.08 10.77 4.46 
Endoplasmic reticulum resident protein 44  Q9BS26 9 7 7 7.67 1.15 15.06 2 1 3 2.00 1.00 50.00 -3.83 
Eukaryotic translation initiation factor 2 subunit 
3  
P41091 3 2 2 2.33 0.58 24.74 5 9 9 7.67 2.31 30.12 3.29 
Glycine-tRNA ligase  P41250 1 1 1 1.00 0.00 0.00 9 10 11 10.00 1.00 10.00 10.00 
Growth factor receptor-bound protein 2  P62993 7 6 7 6.67 0.58 8.66 1 1 1 1.00 0.00 0.00 -6.67 
Histidine--tRNA ligase, cytoplasmic P12081 5 6 8 6.33 1.53 24.12 1 1 1 1.00 0.00 0.00 -6.33 
Histone H3.1  P68431 1 1 1 1.00 0.00 0.00 8 7 4 6.33 2.08 32.87 6.33 
Histone H3.2  Q71DI3 1 1 1 1.00 0.00 0.00 8 5 5 6.00 1.73 28.87 6.00 
Interleukin enhancer-binding factor 3  Q12906 1 3 1 1.67 1.15 69.28 11 7 5 7.67 3.06 39.85 4.60 
NAD(P) transhydrogenase, mitochondrial  
(NNT) 
Q13423 1 1 1 1.00 0.00 0.00 5 9 8 7.33 2.08 28.39 7.33 
Prothymosin alpha  P06454 1 1 1 1.00 0.00 0.00 8 17 17 14.00 5.20 37.12 14.00 
Ribonucleoside-diphosphate reductase large 
subunit  
P23921 9 13 11 11.00 2.00 18.18 4 4 3 3.67 0.58 15.75 -3.00 
Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit  
P62136 14 12 12 12.67 1.15 9.12 9 1 1 3.67 4.62 125.97 -3.45 
Tubulin-tyrosine ligase-like protein 12  Q14166 9 10 8 9.00 1.00 11.11 2 4 3 3.00 1.00 33.33 -3.00 
 
a,first replicate; b,second replicate; c,third replicate; d,number of normalized spectral counts (NSC); e,standard deviation of the averaged NSC; f,coefficient of variation (CV%); g,fold regulation in 
expression HL60 DCA treated cells vs non-treated cells. 
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Table 11. Proteins significantly altered (OPLS-DA, Mann-Whitney, p<0,05) in HL-60 cells after DCA 
treatment 
 
Description Accession Number UniProtkB Fold regulation 
ADP/ATP translocase 2 (ANT2) ADT2_HUMAN P05141 -32.67 
ADP-ribosylation factor 4 ARF4_HUMAN P18085 5.67 
ADP-ribosylation factor 5  ARF5_HUMAN P84085 7.33 
Asparagine-tRNA ligase, cytoplasmic SYNC_HUMAN O43776 4.46 
Endoplasmic reticulum resident protein 44  ERP44_HUMAN Q9BS26 -3.83 
Eukaryotic translation initiation factor 2 subunit 3  IF2G_HUMAN P41091 3.29 
Glycine-tRNA ligase  SYG_HUMAN P41250 10.00 
Growth factor receptor-bound protein 2  GRB2_HUMAN P62993 -6.67 
Histidine-tRNA ligase, cytoplasmic  SYHC_HUMAN P12081 -6.33 
Histone H3.1  H31_HUMAN P68431 6.33 
Histone H3.2  H32_HUMAN Q71DI3 6.00 
Interleukin enhancer-binding factor 3  ILF3_HUMAN Q12906 4.60 
NAD(P) transhydrogenase, mitochondrial (NNT) NNTM_HUMAN Q13423 7.33 
Prothymosin alpha  PTMA_HUMAN P06454 14.00 
Ribonucleoside-diphosphate reductase large subunit  RIR1_HUMAN P23921 -3.00 
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  PP1A_HUMAN P62136 -3.45 
Tubulin-tyrosine ligase-like protein 12  TTL12_HUMAN Q14166 -3.00 
 
Data report proteins differentially modulated (above the cutoff of 3 fold of induction or below the cutoff of -3 fold of 
reduction) after DCA 30mM treatment in HL-60 cells. 
 
Network analysis, using MetaCore bioinformatic tools of the 17 significantly deregulated 
proteins, revealed the involvement of Cellular metabolic processes as the main GO processes 
altered by DCA treatment (Figure 13A). In addition, when MetaCore software was used to map the 
shortest paths of interactions among the differentially expressed proteins, 12 out of 17 proteins were 
brought together with p21 as the hub of the identified network (Figure 13B). Among the significantly 
deregulated proteins there was a relevant modulation of two mitochondrial proteins, i.e. the down-
regulation of ANT2 (ADP/ATP translocase 2), a bi-functional protein that mediates the vital exchange 
of cytosolic ADP and mitochondrial ATP and participates to mitochondrial membrane permeability 
transition pore [143] and the up-regulation of NNT (NAD(P) transhydrogenase, mitochondrial), an 
integral protein located in the inner mitochondrial membrane that contributes to an elevated 
mitochondrial NADPH/NADP(+) ratio. 
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A    B 
 
 
Figure 13. Role of p21 in mediating the anti-leukemic activity of DCA in p53null leukemic cells. In A-B, 
proteomic profiling in HL-60 cells upon DCA treatment revealed significant different (at least 3 folds) levels for 17 
proteins in DCA treated cultures compared to the untreated cells (Table 11). In A, the top ten GO processes, 
prioritized in according to p-value, in response to DCA treatment is shown. In B, the protein network generated by 
the shortest path algorithm using the list of the differently expressed proteins (more than 3 fold induction/reduction) 
is reported. Nodes represent proteins and the different shapes of the nodes represent the functional class of the 
proteins. Circles evidence protein identified in our proteomic analysis. Lines connecting the nodes indicate indirect 
interactions (activation, induction, modification) or direct binding; the arrowheads indicate the direction of the 
interaction. Blue broken line circles highlight network hubs as indicated by network statistics.  
 
Interestingly p21 was directly connected with interleukin enhancer-binding factor 3 (ILF3, 
also known as NFAT-90 or NF90), a regulator of p21 at transcriptional and post-transcriptional levels 
[144,145] (Figure 14) and prothymosin alpha (PTMA), that exerted a broader effect on transcription, 
due to its ability to interact with histones and affect chromatin remodeling processes [146].  
Numerous reports document the direct interaction of the heterodimeric nuclear factor 90/ 
nuclear factor 45 complex (ILF3/ILF2) with DNA, acting as regulator of gene expression at 
transcriptional level; indeed this complex has been shown to regulate the activity of several cellular 
promoters through direct interaction with a specific target DNA sequence, the purine-rich antigen 
receptor response element/nuclear factor of activated T-cells (NF-AT) binding site (ARRE)/NF-AT 
[144]. The same recognition motif has been predicted to be present in the regulatory region of the 
p21/CDKN1A gene through bioinformatics tool (MatInspector analyses of Genomatix), with 
significantly high similarity score. Nevertheless, in addition to the above described role in 
transcriptional control, it is documented that NF45 and NF90 also interact with RNA, acting at 
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multiple levels: indeed NF90 regulates the post-transcriptional stabilization of RNA molecules, 
nuclear export to cytoplasm, RNA splicing and translation [144]. In particular, the 3'-UTR of both the 
human and murine p21 mRNA is predicted to adopt secondary structures that includes regions of 
double-stranded RNA and hairpin-loops with AU-rich elements which represent binding targets for 
NF90. Gene-targeted NF90(-/-) mice, completely lacking NF90 protein, demonstrate severely 
reduced expression of p21, both at mRNA and at protein level, compared to wild-type and 
heterozygote littermates, leading to the conclusion that NF90 is a critical determinant of post-
transcriptional stabilization of p21 mRNA, stabilizing the mRNA against rapid degradation, and 
consequently contributing to the up-regulation of p21 gene expression [145]. 
 
 
 
Figure 14. Mechanisms of p21/CDKN1A gene regulation by ILF3. Schematic representation of the 
predicted ILF3 binding sites on the regulatory region of the human p21/CDKN1A gene (A) and on the p21 mRNA 
3’-UTR secondary structure (B), supporting the transcriptional and post-transcriptional regulation of p21/CDKN1A 
by ILF3. In A, the purine-rich NF-AT/ILF3 binding sites, predicted by computational analysis (MatInspector analyses 
of Genomatix), are evidenced in the regulatory region of the human p21/CDKN1A gene. In B, mRNA 3’-UTR 
secondary structure analysis (RNA fold program from the Vienna RNA Package, used to perform the secondary 
structure predictions and folding calculations) of a partial region of p21/CDKN1A is represented; arrows indicate the 
AU-rich elements in the sequence recognized by ILF3, involved in the stabilization of p21 mRNA. 
 
 
Role of ILF3-p21 axis in DCA induced cytotoxicity  
On the base of the proteomic results, we next tested the potential role of p21 in mediating 
the anti-leukemic activity of DCA using again the p53null HL-60 cells as model system, by utilizing 
siRNAs to attenuate p21 expression. As shown in Figure 15A, once confirmed the effective knock-
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down of p21 expression through quantitative RT-PCR both at baseline and after DCA treatment, we 
observed a significant (p<0.05) reduction in DCA-induced cytotoxicity in p21 siRNA transfected cells 
with respect to cells transfected with a scrambled control siRNA. This set of data confirmed that p21 
plays a central role in mediating cytotoxicity of DCA not only in p53wild-type B leukemic cells but also in 
p53deficient leukemic cells. 
Subsequently, in order to disclose the mechanism of p21 regulation by DCA, we attenuate 
ILF3 expression. As shown in Figure 13B, the knock-down of ILF3 expression by siRNA transfection 
determined the concomitant reduction in p21 mRNA levels both in untreated culture and upon DCA 
exposure, consistently with the documented role of ILF3 as a regulator of p21 at transcriptional and 
post-transcriptional levels. The involvement of ILF3 in DCA anti-leukemic signaling pathway, in 
absence of functional p53 pathway, was revealed by the effect of its down-modulation in attenuating 
DCA cytotoxicity, similarly to the effect resulted by p21 gene silencing (Figure 15B-C).  
 
 
 
Figure 15. Role of p21 and ILF3 pathway in mediating the anti-leukemic activity of DCA in p53null leukemic 
cells. In A-B, HL-60 cells were transfected with either control scrambled (scr) siRNA, or p21 siRNA (A) or ILF3 
siRNA (B) before treatment with DCA (30 mM). After transfection, levels of p21 mRNA were analyzed by 
quantitative RT-PCR (A-B). Data are expressed as arbitrary units (a.u.). In parallel transfected cultures were 
analyzed for cell viability upon exposure to DCA; results are expressed as percentage of viable cells with respect to 
the control cultures (set to 100%). Data are reported as means±SD of results from three independent experiments, 
each performed in duplicate (Mann-Whitney rank-sum test; asterisk, p<0.05). In C, a schematic representation of 
the potential p53-independent pathway mediating the anti-leukemic activity of DCA is shown.  
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On the other hand, knock-down of ILF3 expression in p53wilde-type cells did not determine 
significant modulatory effects on p21 (both in untreated culture and upon DCA exposure; Figure 16). 
Although this is not a direct evidence of the role of p53 in p21 regulation, nevertheless it suggests a 
prominent role of p53-pathway in the p21 induction by DCA in p53wild-type cells. 
 
 
 
Figure 16. Analysis of the DCA-ILF3-p21 axis in p53wild-type leukemic cells. In A, p53wild-type JVM-2 cells 
were transfected with either control scrambled (scr) siRNA or ILF3 siRNA, before treatment with DCA (30 mM). 
Upon ILF3 silencing, levels of p21 mRNA were assessed by quantitative RT-PCR, both in untreated and DCA 
treated cells. Data are expressed as arbitrary units (a.u.) and reported as means±SD of results from three 
independent experiments, each performed in duplicate. In B, a schematic representation of the hypothetic p53-
dependent and p53-independent pathways mediating the p21 modulation in response to DCA. 
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Discussion 
 
 
 
 
Recently it has been proposed that the metabolic phenotype in cancer is to be ascribed to a 
potentially plastic mitochondrial remodeling that results in the inhibition of oxidative phosphorylation, 
improvement in glycolysis and reduction in apoptosis level. Cancer associated oxidative stress and 
aerobic glycolysis have been documented to be active also in hematological malignancies, including 
B-CLL [85], with the prevalence of oxidative stress, adaptation to permanent intrinsic oxidative stress 
and mitochondrial biogenesis [82]. Thus, agents directed against these unique metabolic features of 
cancer cells might represent an opportunity to improve current treatments, in particular with the aim 
of overcoming drug resistance in leukemic cells. 
In this study, we have demonstrated for the first time that the mitochondria-targeting small 
molecule DCA exerts cytotoxic activity in vitro at comparable levels in both primary p53wild-type and 
p53mutated B-CLL patient cells, as well as in p53wild-type and in p53mutated/null leukemic cell lines, in a 
range of concentrations previously used by other authors in in vitro models of solid tumors [101-
103,105]. On the other hand, DCA marginally affected cell viability of primary normal peripheral 
blood mononuclear cells obtained from healthy individuals. These findings are particularly 
remarkable since patients harboring TP53 mutations have a poor prognosis and still limited 
therapeutic options [31]. Indeed, p53 mutations are known to interfere with the normal response of 
human cells to oxidative stress. The failure of p53 mutant-expressing cells to restore a reducing 
oxidative environment is often accompanied by increased survival [147], which represents an aspect 
of the gain of function of the pro-oncogenic activity of mutated TP53. In considering the potential 
relevance of our in vitro studies, suggesting the therapeutic use of DCA as anti-leukemic molecule, it 
should be underlined that there are 40 years of human experience in the treatment of lactic acidosis 
and inherited mitochondrial diseases, with mechanistic studies of DCA in human tissues after oral 
use, pharmacokinetic and toxicity data from randomized studies [148]. Moreover, preclinical studies 
demonstrated the DCA efficacy against solid tumors, as well as on multiple myeloma, and confirmed 
a relatively low toxicity of this molecule with good tolerability and low incidence of adverse effects. In 
fact, DCA is currently being included in phase I/II clinical trials for glioblastoma, gliomas and other 
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solid tumors [106]. These data support an easy translation of DCA in clinical settings. An additional 
interesting characteristic of this molecule is its low cost. 
At molecular level, by using as a model system a set of B leukemic cell lines, we have 
demonstrated that DCA induces both cell cycle arrest in the G1 phase, senescence and apoptosis 
through both p53-dependent and p53-independent pathways. In the first part of our study, focused 
on p53 wild-type B-CLL (which represent the great majority), our investigations revealed that DCA 
induced post-transcriptional modifications of p53 with activation of the p53 transcriptional activity, as 
documented by the induction of several canonical p53 target genes, such as MDM2, p21 and PUMA. 
Another interesting finding was the ability of DCA to potently synergize with Nutlin-3, a non-genotoxic 
activator of the p53 pathway, in promoting cytotoxicity in B leukemic cell lines as well as in primary 
B-CLL patient cells, with significantly less toxicity on normal PBMC. Although the contribution of the 
transcriptional activity of p53 in promoting leukemic cytotoxicity is still under debate, as 
transcriptional independent activities have also been demonstrated in previous studies performed 
with Nutlin-3 [29,30], our data demonstrated the existence of a correlation between the ability to 
promote the transcription of p53 transcriptional targets, and in particular p21, and the synergistic 
cytotoxic activity in response to the DCA+Nutlin-3 treatment. Interestingly, while the DCA+Nutlin-3 
combination was extremely efficient in inducing the transcription of p21 in both primary B-CLL patient 
samples and B leukemic cell lines, it was significantly less efficient when added to primary normal 
PBMC. The demonstration that DCA+Nutlin-3 potently synergized in inducing the transcriptional 
activation of p21 is noteworthy since the transcriptional induction of p21 has been involved in 
mediating the therapeutic effect of chemotherapeutic drugs in B-CLL [140]. 
As anticipated above, DCA exhibits anti-leukemic activity also independently of p53 
functionality. DCA efficiently induced mitochondrial damage, documented by morphological 
remodeling of mitochondrial structure, mitochondrial depolarization and reduction in ATP synthesis, 
in all leukemic cell lines investigated independently by the p53 status. Proteomic analyses in p53 null 
leukemic cells revealed a relevant modulation of proteins involved in the metabolic processes 
including proteins of the mitochondrial inner membrane, i.e. the down-regulation of adenine 
nucleotide translocase 2 (ANT2) and the up-regulation of nicotinamide nucleotide transhydrogenase 
(NNT). ANT2 exerts a crucial role in the metabolic adaptation of cancer cells, contributing to the 
maintenance of the mitochondrial membrane potential (ΔΨm) under glycolytic conditions, ensuring 
cell survival upon oxidative phosphorylation impairment and preventing apoptotic cell death [149]. 
NNT contributes to an elevated mitochondrial NADPH/NADP(+) ratio, participating in the defence 
against mitochondrial oxidative stress [150]. 
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In parallel, we documented that DCA induced the transcription of p21 through the induction 
of the transcription factor ILF3 in a p53-independent manner. 
Recent studies confirmed that p21 is necessary for the induction of mitochondrial 
dysfunction observed in senescence and this event maintains a constant DNA damage response 
leading to prolonged cell cycle arrest [151]. P21 prevents cancer cell growth due to its ability to 
transiently or permanently stop proliferation, thus being an important component of tumor suppressor 
mechanisms. Indeed, it has recently been demonstrated that p21 can be down-regulated by several 
microRNA expressed in cancer cells [152,153]. Concurrently, although p21 levels have been found 
elevated in some cancers without signs of growth inhibition [154] and in some experimental settings 
it has been proposed that p21 can actually favor transformation by inhibiting apoptosis [153], other 
studies have recently shown that p21 can also trigger cell death [140,151]. At present, it is not well 
understood how p21 exerts these radically different functions or even if they reside in separate 
domains of the protein. 
 
Conclusions 
In spite of the discrepancies present in the scientific literature, overall our data clearly point 
to the tumor-suppressor activity of p21 in the context of DCA-induced cytotoxicity on both p53wilde-type 
as well as on p53mutated/null B-leukemic cell lines, in agreement with the demonstration that the in vitro 
activation of p21 in B-CLL accurately predicts the therapeutic response in vivo of B-CLL [140].  
Since p53 mutations still represent one of the major negative prognosticators of B-CLL, we 
believe that the therapeutic potential of DCA should be further evaluated possibly in combination with 
other innovative anti-leukemic drugs. 
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